Methotrexate adjuvants to reduce toxicity and methods for using the same

ABSTRACT

Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2′-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.

CROSS-REFERENCE TO RELATED APPLICATIONS

Pursuant to 35 U.S.C. §119 (e), this application claims priority to thefiling date of U.S. Provisional Patent Application Ser. No. 61/033,333filed Mar. 3, 2008; the disclosure of which application is hereinincorporated by reference.

INTRODUCTION

The presence of tetrahydrofolates (THFs) in cells provides importantlife-sustaining processes, such as the biosynthesis, replication andrepair of DNA and RNA. THFs perform this function by providingsubstrates required to complete the biochemical reactions facilitatingthese processes. THFs are biosynthesized intracellularly throughreduction of folic acid by the enzyme dihydrofolate reductase (DHFR) orother dihydrofolate intermediates. The pteridine compound, methotrexate(MTX;N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamicacid), is structurally similar to folic acid (see structures for Folicacid and MTX below).

As a result, MTX can bind to active sites on DHFR and block, bycompetitive inhibition, the formation of THFs needed for the de novosynthesis of the nucleoside thymidine, required for DNA synthesis. Also,folate is needed for purine base synthesis, so all purine synthesis willbe inhibited. Methotrexate, therefore, inhibits the synthesis of DNA,RNA, thymidylates, and proteins and the ability of MTX to inhibitnucleic acid synthesis has been exploited for over 50 years in thetreatment of aberrant cell growth ((Jolivet et al., N Engl J Med;309:1094-1104 (1983); Gangjee, Anti-Cancer Agents in MedicinalChemistry; 7: 524-542 (2007); Assaraf, Metastasis Review; 26: 153-181(2007); Huennekens; Advanced Enzyme Regulation; 34: 397-419 (1994);Walling, Investigational New Drugs; 24: 37-77 (2006); Gangjee, Jain,Hiteshkumar, Current Medicinal Chemistry; 4: 405-410 (2004)). Inparticular, malignant cells typically have a greater need for THFs thannormal cells because they proliferate more rapidly and are thereforemore sensitive to the effect of MTX. In many cases, MTX can be used toselectively impair cancerous cell growth without damaging normal cellgrowth. As a result of its effectiveness against rapidly proliferatingcells, MTX is one of the most widely used anticancer agents indicatedfor the treatment of both solid and hematological cancers. For example,MTX is employed alone or with other treatment modalities in thetreatment of neoplastic diseases such as gestational choriocarcinoma,chorioadenoma destruens, hydatidiform mole, leukemias (for example,acute lymphocytic leukemia), breast carcinoma, epidermoid cancers of thehead and neck, advanced mycosis fungoides (cutaneous T-cell lymphoma),lung carcinoma, non-Hodgkins lymphomas and trophoblastic neoplasms suchas choriocarcinoma, chorioadenoma destruens, hydatidiform mole(Physicians Desk Reference, 60th ed., Thomson Healthcare, Stamford,Conn. (2006); Goodman & Gilman's The Pharmacological Basis ofTherapeutics, 11^(th) ed., McGraw-Hill Columbus, Ohio (2005); The MerckManual of Diagnosis and Therapy 18th ed., John Wiley, Hoboken, N.J.,(2006)).

Moreover, MTX is an effective immunosuppressive agent which can be usedfor the prevention of the graft-versus-host disease resulting fromtissue transplants, as well as for the treatment of inflammatorydiseases such as psoriasis, psoriatic arthritis, rheumatoid arthritisand Crohn's disease (Kokuryo). MTX is frequently used for the treatmentof severe and disabling cases of psoriasis and rheumatoid arthritis(Warren et al., Br. J. Dermatology, 153(5), 869-873 (2005); Cronstein,Pharmacol. Rev., 57(2), 163-172 (2005)).

The numerous patents that have been issued disclosing MTX and MTXanalogs, methods of synthesizing MTX or analogs thereof, and uses forMTX attest to the significance of MTX in treatment of aberrant cellgrowth. For example, U.S. Pat. No. 2,512,572 covers the active agentMTX, and U.S. Pat. Nos. 3,892,801, 3,989,703, 4,057,548, 4,067,867,4,079,056, 4,080,325, 4,136,101, 4,224,446, 4,306,064, 4,374,987,4,421,913, and 4,767,859 claim methods for preparing MTX or potentialintermediates in the synthesis of MTX. Other patents disclose labeledanalogs of MTX, such as U.S. Pat. Nos. 3,981,983, 4,043,759, 4,093,607,4,279,992, 4,376,767, 4,401,592, 4,489,065, 4,622,218, 4,625,014,4,638,045, 4,671,958, 4,699,784, 4,785,080, 4,816,395, 4,886,780,4,918,165, 4,925,662, 4,939,240, 4,983,586, 4,997,913, 5,024,998,5,028,697, 5,030,719, 5,057,313, 5,059,413, 5,082,928, 5,106,950, and5,108,987, wherein MTX is bound to a radionucleotide or fluorescentlabel, amino acid, polypeptide, transferrin or ceruloplasmin,chondroitin or chondroitin sulfate, antibody, or binding partner for aspecific cell-surface receptor of target cells for use in assays of MTX,in timed-release of MTX, as toxins selective for cancer cells, or tofacilitate transport of MTX across membranes or in vivo barriers.

Of the numerous patents issued disclosing methods of using MTX, avariety of patents such as U.S. Pat. Nos. 4,106,488, 4,558,690, and4,662,359 disclose methods of using MTX to treat cancer.

Unfortunately, given the effectiveness and broad applications of MTXtherapy, treatment with this agent involves serious side-effects withsignificant risk to the patient. Since MTX interferes with cellreplication and division, actively proliferating, non-malignant tissuessuch as intestinal mucosa and bone marrow are sensitive to MTX and maydemonstrate impaired growth due to MTX treatment. MTX and a metaboliteof methotrexate, 7-OH-MTX, are also associated with renal and hepatictoxicity when applied in the “high dose regimen” that is typicallyrequired for maximum efficiency (Barak et al., J. American Coll. Nutr.,3, 93-96 (1984); Yazici et al., J. Rheumatol. 29(8), 1586-1589 (2002)).

Damage to the gastrointestinal mucosa is the most debilitating of theside-effects of MTX. Known as mucositis, this complication may occur inthe oral cavity or any other part of the alimentary canal ((Sonis etal., Cancer, 100:1995-2025 (2004)). A type of mucositis that isparticularly troublesome for patients is stomatitis, ulceration of themucosa in the mouth, a condition making eating and swallowing painfuland difficult.

Mucositis decreases the quality of life of cancer patients receivingchemotherapy while increasing their risk of hospitalization (Naidu etal. Neoplasia, 6:423-31 (2004)). It can also result in serious bacterialinfection (Pico et al., Oncologist 3: 446-451 (1998), and McGuire,Support Care Cancer, 11: 435-41 (2003)), often leading to the need touse a feeding tube (Treister and Sonis, Curr Opin Otolaryngol Head NeckSurg.; 15:123-9 (2007)). These complications frequently lead to reduceddoses, or complete cessation, of the chemotherapy thereby reducing theefficacy of the chemotherapy (Sonis et al., Cancer. 100:1995-2025(2004)). Increased need for medical care due to mucositis also resultsin added costs (Scully, Sonis, Diz, Oral Dis.; 12: 229-41 (2006)). Thereis no effective prophylaxis or treatment for mucositis (Sonis et al.,Rev Cancer. 4: 277-284 (2004). Therefore, an adjuvant that ameliorateschemotherapy-induced mucositis could improve patients' quality of lifeand prognosis while reducing the financial burden of cancer therapy.

SUMMARY

Methods of using adjuvants to reduce the toxicity of methotrexate (MTX)in a host are provided. In the subject methods, an effective amount ofan MTX active agent is administered to a host in conjunction with theadministration of an MTX toxicity-reducing adjuvant of the presentinvention, where the MTX active agent and MTX toxicity reducing adjuvantmay be administered sequentially, starting with either the MTX agent orthe toxicity-reducing adjuvant, simultaneously, or a combinationthereof. In certain embodiments, the MTX toxicity-reducing adjuvant is a2,2′-anhydropyrimidine, a derivative thereof or a uridine phosphorylase(UPase) inhibitor. Also provided are compositions for use in practicingthe subject methods, e.g., MTX pharmaceutical compositions havingreduced toxicity and kits that include the same. The subject methods andcompositions find use in a variety of different applications, includingthe treatment of a variety of different disease conditions. An exemplaryapplication illustrating a significant advantage of the methods andcompositions of the invention is the reduction of MTX-induced mucositis.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts a set of results demonstrating the ability of TK-112690,a 2,2′-anhydropyrimidine MTX toxicity-reducing adjuvant according to anembodiment of the invention, to reduce MTX toxicity in flies(viability). In this study, Drosophila melanogaster eggs (50 eggs pervial) were treated with either 0.005 mg TK-112690+0.4 mg MTX (Group 1),0.01 mg TK-112690+0.4 mg MTX (Group 2), 0.04 mg TK-112690+0.4 mg MTX(Group 3), 0.1 mg TK-112690+0.4 mg MTX (Group 4), 0.4 mg MTX alone(Group 5) or saline blank (Group 6). Two vials of eggs for each dosegroup were evaluated for viability (viable flies plus pupae).

FIG. 2 depicts a set of data demonstrating the ability of TK-112690, a2,2′-anhydropyrimidine MTX toxicity-reducing adjuvant according to anembodiment of the invention, to mitigate MTX-induced weight loss in amammal. C57BL/6 mice (10 animals/treatment group) were dosed on Day 1with LPS (5 μg, i.p.). On Day 2, the animals were treated with 200 mg/kgMTX+10 or 30 mg/kg TK-112690 3 hr before and 3 hr after the MTXtreatment. On Day 3, the animals were dosed MTX 100 mg/kg+10 or 30 mg/kgTK±3 hr. On day 8, the Day 8-Day 1 weight was determined and resultssubject to ANOVA. Group 1=saline alone, Group 2=MTX alone, Group 3=LPSalone, Group 4=MTX+LPS, Group 5=10 mg/kg TK-112690+MTX+LPS or Group 6=30mg/kg TK-112690+MTX+LPS.

FIG. 3 depicts a set of data demonstrating the ability of TK-112690, a2,2′-anhydropyrimidine MTX toxicity-reducing adjuvant according to anembodiment of the invention, to mitigate MTX-induced loss of mucosalpermeability in a mammal. C57Bl/6 female mice (n=7) were treatedintraperitoneal (ip) with 100 mg/kg MTX on days 2, 3 and 4 with andwithout 60 mg/kg TK-112690 (ip) three hours before, and after, MTXinjections. On day 7, mucosal barrier injury was estimated by measuringplasma concentrations of orally administered iodixanol determined byHPLC using UV detection (Boxplots with minimum and maximum values (blacklines). Orally administered iodixanol is not absorbed absent an increasein mucosal permeability. Group 1=saline control, Group 2=MTX and Group3=MTX+TK-112690.

FIG. 4 depicts a set a data demonstrating the ability of TK-112690, a2,2′-anhydropyrimidine MTX toxicity-reducing adjuvant according to anembodiment of the invention, to mitigate MTX-induced infection measuredas elevated WBC concentrations in a mammal. C57BL/6 mice (n=10/dosegroup), treated i.p. 50 mg/kg MTX on Day 1, 2, 3, 4, 6 and 8 along with60 mg/kg TK-1126901.p. 3 hr±MTX followed by single daily doses TK-112690on days not treated with MTX. On Day 11, the animals were sacrificed andhematology performed on the resulting blood. Group 1=saline control,Group 2=MTX control and Group 3=MTX+TK-112690.

FIG. 5 depicts a set of data demonstrating that TK-112690, a2,2′-anhydropyrimidine MTX toxicity-reducing adjuvant according to anembodiment of the invention, does not interfere with MTX cytotoxicity inhuman acute T-cell lymphoblastic leukemia cells (in vitro growth). Inthis study, CCRF-CEM cells purchased from ATCC were cultured and then 12tubes containing approximately 10⁶ cells each treated for 72 hours withmedia (Group1), MTX 0.03 μM (Group2), MTX+Leucovorin 1 μM (Group3),MTX+Leucovorin 10 μM (Group4), MTX+Leucovorin 100 μM (Group5),MTX+TK-112690 1 μM (Group6), MTX+TK-112690 10 μM (Group7) andMTX+TK-112690 100 μM (Group8). Tests with Leucovorin and TK-112690 alonewere not statistically different than control (Group 1). Viability wasmeasured as percent reduction of alamarBlue absorbance.

FIG. 6 depicts a set of data demonstrating that TK-112690, a2,2′-anhydropyrimidine MTX toxicity-reducing adjuvant according to anembodiment of the invention, does not interfere with MTX cytotoxicity inhuman lymphoma cells (in vivo growth) implanted in a mammal. In thisstudy, n=10 SCID mice per dose group were treated with CCRF-CEM humantumors and the tumors allowed to grow to a size of approximately 100 mg.Then the animals were treated by intraperitoneal (ip) injection witheither control 20% DMSO/80% PBS (1×/day)×5 days (Group 1), MTX 7.5mg/kg/injection (1×/day)×5 days (Group 2) or MTX 7.5 mg/kg/inj.(1×/day)×5 days+TK-112690 30 mg/kg/inj.±3 hrs (group 3). The Figureprovides tumor sizes in each of the 3 groups on Day 27 of the study.

FIG. 7 depicts a set of data demonstrating that TK-112690, a2,2′-anhydropyrimidine MTX toxicity-reducing adjuvant according to anembodiment of the invention, does not interfere with MTX cytotoxicity inhuman lymphoma cells (in vitro growth). In this study, AS283 cells weregrown in RPMI-1640 supplemented with L-glutamine dipeptide, sodiumpyruvate, HEPES, and 10% FBS. AS283 cells were used to seed three96-well plates with 10,000 cells/well in a total volume of 50 μL. Mediumalone wells were seeded 100 μL medium. Plates were incubated overnight.The following day, 25 μL of the TK-112690 and MTX stock solutions wereadded to the appropriate wells. TK-112690 was added first, followed byMTX in all wells. 25 μL of vehicle was added to TK-112690 alone wells.25 μL of vehicle and 25 μL medium were added to vehicle control wells,and 50 μL medium was added to cell control wells. Cell viability wasmeasured using CellTiter-Glo and DOX (10 μM) was used as a referencestandard. The plates were incubated at 37° C., 5% CO₂ for 72 hours thenremoved from the incubator and placed on the bench at room temperaturefor 30 min. The plates were not stacked or shaken. 100 μL CellTiter-Gloreagent was added and mixed for 2 min, followed by a further 10 minincubation at room temperature. Luminescence was recorded on TriLux. Inthis study, MTX was cytotoxic to the AS283 cancer cells, but TK-112690(1, 10, 100 μM) did not diminish the cytotoxicity of MTX (0.01, 0.03,0.1, 0.3, 1.0, 3.0, 10, 100 μM). In FIG. 7, the top chart provides theIC₅₀ curve for AS283 human lymphoma cells treated for 72 hours witheither MTX or MTX+TK-112690 at a concentration of 100 and 10 μM (TopChart) or while the bottom chart provides the IC₅₀ curve for MTX andMTX+TK-112690 1.0 μM.

FIG. 8 depicts a set of data demonstrating that TK-112690, a2,2′-anhydropyrimidine MTX toxicity-reducing adjuvant according to anembodiment of the invention, does not interfere with MTX cytotoxicity inhuman lymphoma cells (in vivo growth) implanted into a mammal.Six-week-old male SCID mice were implanted with fragments of AS283 humanlymphoma tumors. The tumors were allowed to reach 75-198 mg in weight(75-198 mm³ in size) before the start of treatment. The experimentconsisted of two treatment groups and one vehicle-treated control group,with ten animals per group, for a total of 30 mice on the first day oftreatment.

TK-112690 was administered by ip injection [twice every 2 days for 5injections with six hour interval (q6h×2, q2d×5)] at a dosage of 30mg/kg/injection. MTX was administered by ip injection q2d×5 at a dosageof 5.0 mg/kg/injection three hours after the TK-112690 injection. Thecontrol group was treated with both vehicles, which were administered onthe corresponding compound schedules.

The subcutaneous (sc) tumors were measured and the animals were weighedthrice weekly starting the day of the first treatment. The study wasterminated twenty one days after tumor implantation. Tumors in thevehicle-treated control group grew to the evaluation point in all tenmice. The median tumor reached 4,387 mg in 21 days. The MTX treatmentdelayed the growth of AS283 lymphoma xenografts with a median tumorweight value 2.8% of the control on day 21 and a median tumor weightvalue of 24.7% (40.0 mg) smaller than the median tumor weight value atthe start of treatment (162 mg). Administration of TK-112690 combinedwith MTX delayed the growth with a median tumor weight value 3.5% of thecontrol on day 21 and a median tumor weight value 5.6% (9.0 mg) smallerthan the median tumor weight value at the start of treatment (162 mg).There was no statistical difference between the MTX (Group 2) andMTX+TK-112690 (Group 3) tumor volumes (p=1.0) but both groups werestatistically highly different (p<0.01) than the tumor volumes for thesaline treated animals (Group1). Both groups receiving MTX werestatistically identical using Bonferroni one-way ANOVA. Boxplots showthe group median (black line), interquartile range (box) and outliers.

FIG. 9 depicts a set of data demonstrating that TK-112690, a2,2′-anhydropyrimidine MTX toxicity-reducing adjuvant according to anembodiment of the invention inhibits both murine and human uridinephosphorylase (UPase). A range of TK-112690 doses were studied for thetheir ability to prevent metabolic breakdown of uridine through the invitro inhibition of mouse and human small intestinal UPase enzyme. UPaseactivity was determined by HPLC analysis using UV detection of uracilconcentration (UPase catabolizes uridine into uracil andribose-1-phosphate). The UPase enzyme material was prepared fromhomogenized mouse and human being small intestinal tissue. TK-112690 wasdissolved in water (50 mg/ml) and analyzed for UPase inhibition inaqueous solution containing 5 mM uridine, 0.01 M Tris, 0.01 M phosphate,1 mM EDTA, and 1 mM DTT. Reactions were performed at 37° C. at pH of7.3.

TK-11260 inhibition of mouse and human UPase was determined frommeasurements of uracil determined in homogenates by reverse phase HPLCusing UV detection. The results demonstrate that TK-112690 inhibitsmouse small intestinal UPase enzyme, with a IC₅₀ value of 12.5 μM.TK-112690 inhibits human small intestinal UPase enzyme, with a an IC₅₀value of 20.0 μM.

FIG. 10 depicts a set of data further demonstrating that TK-112690, a2,2′-anhydropyrimidine MTX toxicity-reducing adjuvant according to anembodiment of the invention, is a uridine phosphorylase (UPase)inhibitor. Embryos of UPase knockout (19519) Drosophila melanogasterwere orally exposed to a dose range of MTX doses in food admix. Embryosof Wild-type (Oregon-R) were orally exposed to the same dose range ofMTX in presence and absence of 0.04 mg TK-112690. Scoring was based onlife or death 15 days after initiation of MTX exposure. UPase knockoutD. melanogaster (19519) was seen to be resistant to lethal effects of adose-range (0.001, 0.01, 0.05, 0.1, 0.2, 0.4 mg) of orally administeredMTX. Wild-type D. melanogaster are sensitive to lethal effects of ≧0.1mg MTX. Wild-type D. melanogaster are resistant to lethal effects of adose-range (0.001, 0.01, 0.05, 0.1, 0.2, 0.4 mg) of orally administeredMTX in the presence of 0.04 mg TK-112690.

As seen in FIG. 10, Methotrexate doses 0.1 mg are lethal to wild-typeflies 15 days after the initiation of MTX exposure. Inhibition of UPaseactivity by the addition of 0.04 mg TK-112690 provides protection oflethality from doses as high as 0.4 mg of methotrexate. UPase mutantflies administered a dose range of methotrexate exhibit similarprotection from methotrexate lethality as seen in wild-type fliesadministered methotrexate combined with TK-112690. Furthermore, theaddition of TK-112690 into UPase mutant flies treated with a dose rangeof methotrexate does not provide added protection from methotrexatetoxicities.

FIG. 11 depicts a set of data demonstrating that TK-112690, a2,2′-anhydropyrimidine MTX toxicity-reducing adjuvant according to anembodiment of the invention, increased concentrations of uridine whenadministered to mice. In this study, CD-1 female mice were injected ipwith 120 mg/kg TK-112690 and plasma from the animals analyzed by HPLCusing UV detection for TK-112690 and uridine. Concentrations of uridineand TK-112690 in plasma samples collected 0.08, 0.50, 1, 2, 4 or 12hours post TK-112690 injection were determined by HPLC using UVdetection. Plasma concentrations of TK-112690 increased with increasingdoses of TK-112690 administered ip. An increase in plasma uridine wasnoted almost immediately following administration of TK-112690. At 0.5hour post TK-112690 dose, a 100 μg/mL plasma concentration TK-112690 isassociated with a plasma uridine concentration of approximately 2 μg/mLof uridine (baseline uridine concentration approximately 0.5 μg/mL). Asexpected, inhibition of UPase by TK-112690 results in elevation ofplasma uridine.

DEFINITIONS

When describing the compounds, pharmaceutical compositions containingsuch compounds, and methods of using such compounds and compositions,the following terms have the following meanings unless otherwiseindicated. It should also be understood that any of the moieties definedforth below may be substituted with a variety of substituents, and thatthe respective definitions are intended to include such substitutedmoieties within their scope.

“Acyl” refers to a radical —C(O)R, where R is hydrogen, alkyl,cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroalkyl, orheteroaryl as defined herein. Representative examples include, but arenot limited to, formyl, acetyl, cylcohexylcarbonyl,cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl and the like.

“Acylamino” refers to a radical —NR′C(O)R, where R′ is hydrogen, alkyl,cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl,heteroarylalkyl and R is hydrogen, alkyl, alkoxy, cycloalkyl,heterocycloalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl orheteroarylalkyl, as defined herein. Representative examples include, butare not limited to, formylamino, acetylamino, cyclohexylcarbonylamino,cyclohexylmethyl-carbonylamino, benzoylamino, benzylcarbonylamino andthe like.

“Acyloxy” refers to the group —OC(O)H, —OC(O)-alkyl, —OC(O)-aryl or—OC(O)— cycloalkyl.

“Aliphatic” refers to hydrocarbyl organic compounds or groupscharacterized by a straight, branched or cyclic arrangement of theconstituent carbon atoms and an absence of aromatic unsaturation.Aliphatics include, without limitation, alkyl, alkylene, alkenyl,alkynyl and alkynylene. Aliphatic groups typically have from 1 or 2 to 6or 12 carbon atoms.

“Alkenyl” refers to monovalent olefinically unsaturated hydrocarbylgroups having up to about 11 carbon atoms, particularly, from 2 to 8carbon atoms, and more particularly, from 2 to 6 carbon atoms, which canbe straight-chained or branched and having at least 1 and particularlyfrom 1 to 2 sites of olefinic unsaturation. Particular alkenyl groupsinclude ethenyl (—CH═CH₂), n-propenyl (—CH₂CH═CH₂), isopropenyl(—C(CH₃)═CH₂), vinyl and substituted vinyl, and the like.

“Alkoxy” refers to the group —O-alkyl. Particular alkoxy groups include,by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy,tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, andthe like.

“Alkoxycarbonyl” refers to a radical —C(O)-alkoxy where alkoxy is asdefined herein.

“Alkoxycarbonylamino” refers to the group —NRC(O)OR′ where R ishydrogen, alkyl, aryl or cycloalkyl, and R′ is alkyl or cycloalkyl.

“Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groupsparticularly having up to about 12 or 18 carbon atoms, more particularlyas a lower alkyl, from 1 to 8 carbon atoms and still more particularly,from 1 to 6 carbon atoms. The hydrocarbon chain may be eitherstraight-chained or branched. This term is exemplified by groups such asmethyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl,n-hexyl, n-octyl, tert-octyl and the like. The term “alkyl” alsoincludes “cycloalkyls” as defined herein.

“Alkylene” refers to divalent saturated aliphatic hydrocarbyl groupsparticularly having up to about 12 or 18 carbon atoms and moreparticularly 1 to 6 carbon atoms which can be straight-chained orbranched. This term is exemplified by groups such as methylene (—CH₂—),ethylene (—CH₂CH₂—), the propylene isomers (e.g., —CH₂CH₂CH₂— and—CH(CH₃)CH₂—) and the like.

“Alkynyl” refers to acetylenically unsaturated hydrocarbyl groupsparticularly having up to about 12 or 18 carbon atoms and moreparticularly 2 to 6 carbon atoms which can be straight-chained orbranched and having at least 1 and particularly from 1 to 2 sites ofalkynyl unsaturation. Particular non-limiting examples of alkynyl groupsinclude acetylenic, ethynyl (—C≡CH), propargyl (—CH₂C≡CH), and the like.

“Amino” refers to the radical —NH₂.

“Amino acid” refers to any of the naturally occurring amino acids (e.g.Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys,Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D, L, or DL form. Theside chains of naturally occurring amino acids are well known in the artand include, for example, hydrogen (e.g., as in glycine), alkyl (e.g.,as in alanine, valine, leucine, isoleucine, proline), substituted alkyl(e.g., as in threonine, serine, methionine, cysteine, aspartic acid,asparagine, glutamic acid, glutamine, arginine, and lysine), alkaryl(e.g., as in phenylalanine and tryptophan), substituted arylalkyl (e.g.,as in tyrosine), and heteroarylalkyl (e.g., as in histidine).

“Aminocarbonyl” refers to the group —C(O)NRR where each R isindependently hydrogen, alkyl, aryl or cycloalkyl, or where the R groupsare joined to form an alkylene group.

“Aminocarbonylamino” refers to the group —NRC(O)NRR where each R isindependently hydrogen, alkyl, aryl or cycloalkyl, or where two R groupsare joined to form an alkylene group.

“Aminocarbonyloxy” refers to the group —OC(O)NRR where each R isindependently hydrogen, alkyl, aryl or cycloalkyl, or where the R groupsare joined to form an alkylene group.

“Amino-containing saccharide group” refers to a saccharide group havingan amino substituent. Representative amino-containing saccharide includeL-vancosamine, 3-desmethyl-vancosamine, 3-epi-vancosamine,4-epi-vancosamine, acosamine, actinosamine, daunosamine,3-epi-daunosamine, ristosamine, N-methyl-D-glucamine and the like.

“Aralkyl” or “arylalkyl” refers to an alkyl group, as defined above,substituted with one or more aryl groups, as defined above.

“Aryl” refers to a monovalent aromatic hydrocarbon group derived by theremoval of one hydrogen atom from a single carbon atom of a parentaromatic ring system. Typical aryl groups include, but are not limitedto, groups derived from aceanthrylene, acenaphthylene,acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene,fluoranthene, fluorene, hexacene, hexaphene, hexylene, as-indacene,s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene,ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene,phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene,rubicene, triphenylene, trinaphthalene and the like. Particularly, anaryl group comprises from 6 to 14 carbon atoms.

“Aryloxy” refers to —O-aryl groups wherein “aryl” is as defined herein.

“Autoimmune disease” or “autoimmune condition” refers an illness thatoccurs when the body tissues are attacked by its own immune system.Examples of autoimuune disease or conditions include multiple sclerosis,ankylosing spondylitis, Crohn's disease, arthritis, psoriasis, Behçet'sdisease and psoriatic arthritis.

Azido” refers to the radical —N₃.

“Carbohydrate” means a mono-, di-, tri-, or polysaccharide, wherein thepolysaccharide can have a molecular weight of up to about 20,000, forexample, hydroxypropyl-methylcellulose or chitosan. “Carbohydrate” alsoencompasses oxidized, reduced or substituted saccharide monoradicalcovalently attached to the anhydropyrimidine (e.g., anhydrothymidine oranhydrouridine), or derivative thereof any atom of the saccharidemoiety, e.g., via the aglycone carbon atom. The “mono-, di-, tri-, orpolysaccharide” can also include amino-containing saccharide groups.Representative “carbohydrate” include, by way of illustration, hexosessuch as D-glucose, D-mannose, D-xylose, D-galactose, vancosamine,3-desmethyl-vancosamine, 3-epi-vancosamine, 4-epi-vancosamine,acosamine, actinosamine, daunosamine, 3-epi-daunosamine, ristosamine,D-glucamine, N-methyl-D-glucamine, D-glucuronic acid,N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, sialyic acid, iduronicacid, L-fucose, and the like; pentoses such as D-ribose or D-arabinose;ketoses such as D-ribulose or D-fructose; disaccharides such as2-O-(α-L-vancosaminyl)-β-D-glucopyranose-,2-O-(3-desmethyl-α-L-vancosaminyl)-β-D-glucopyranose, sucrose, lactose,or maltose; derivatives such as acetals, amines, acylated, sulfated andphosphorylated sugars; oligosaccharides having from 2 to 10 saccharideunits. The saccharides can be either in their open, r pyranose orfuranose forms.

“Carboxyl” refers to the radical —C(O)OH.

“Cyano” refers to the radical —CN.

“Cycloalkenyl” refers to cyclic hydrocarbyl groups having from 3 to 10carbon atoms and having a single cyclic ring or multiple condensedrings, including fused and bridged ring systems and having at least oneand particularly from 1 to 2 sites of olefinic unsaturation. Suchcycloalkenyl groups include, by way of example, single ring structuressuch as cyclohexenyl, cyclopentenyl, cyclopropenyl, and the like.

“Cycloalkyl” refers to cyclic hydrocarbyl groups having from 3 to about10 carbon atoms and having a single cyclic ring or multiple condensedrings, including fused and bridged ring systems, which optionally can besubstituted with from 1 to 3 alkyl groups. Such cycloalkyl groupsinclude, by way of example, single ring structures such as cyclopropyl,cyclobutyl, cyclopentyl, cyclooctyl, 1-methylcyclopropyl,2-methylcyclopentyl, 2-methylcyclooctyl, and the like, and multiple ringstructures such as adamantanyl, and the like.

“Heterocycloalkyl” refers to a stable heterocyclic non-aromatic ring andfused rings containing one or more heteroatoms independently selectedfrom N, O and S. A fused heterocyclic ring system may includecarbocyclic rings and need only include one heterocyclic ring. Examplesof heterocyclic rings include, but are not limited to, piperazinyl,homopiperazinyl, piperidinyl and morpholinyl.

“Halo” or “halogen” refers to fluoro, chloro, bromo and iodo. Halogroups can be either fluoro or chloro.

“Hetero” when used to describe a compound or a group present on acompound means that one or more carbon atoms in the compound or grouphave been replaced by a nitrogen, oxygen, or sulfur heteroatom. Heteromay be applied to any of the hydrocarbyl groups described above such asalkyl, e.g. heteroalkyl, cycloalkyl, e.g. heterocycloalkyl, aryl, e.g.heteroaryl, cycloalkenyl, e.g., heterocycloalkenyl, cycloheteroalkenyl,e.g., heterocycloheteroalkenyl and the like having from 1 to 5, andparticularly from 1 to 3 heteroatoms. A heteroatom is any atom otherthan carbon or hydrogen and is typically, but not exclusively, nitrogen,oxygen, sulfur, phosphorus, boron, chlorine, bromine, or iodine. Anunsubstituted heteroatom refers to a pendant heteroatom such as anamine, hydroxyl and thiol. A substituted heteroatom refers to aheteroatom that is other than a pendant heteroatom.

“Heteroaryl” refers to a monovalent heteroaromatic group derived by theremoval of one hydrogen atom from a single atom of a parentheteroaromatic ring system. Typical heteroaryl groups include, but arenot limited to, groups derived from acridine, arsindole, carbazole,β-carboline, chromane, chromene, cinnoline, furan, imidazole, indazole,indole, indoline, indolizine, isobenzofuran, isochromene, isoindole,isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine,oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline,phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole,pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline,quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole,thiophene, triazole, xanthene, and the like. The heteroaryl group can bea 5-20 membered heteroaryl, or 5-10 membered heteroaryl. Particularheteroaryl groups are those derived from thiophen, pyrrole,benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole,oxazole and pyrazine.

“Hydroxyl” refers to the radical —OH.

“Nitro” refers to the radical —NO₂.

“Peptide” refers to a polyamino acid containing up to 2, 5, 10, or about100 amino acid residues.

“Polypeptide” means polyamino acid containing from about 100 amino acidunits to about 1,000 amino acid units, from about 100 amino acid unitsto about 750 amino acid units, or from about 100 amino acid units toabout 500 amino acid units.

“Proliferative disease” or “proliferative condition” refers to a diseaseor condition featuring pathologic growth as an underlying pathology.Examples include cancer, arthritis and psoriasis.

“Side-effect” means an undesirable adverse consequence of drugadministration such as mucositis associated with administration ofmethotrexate.

“Stereoisomer” as it relates to a given compound is well understood inthe art, and refers to another compound having the same molecularformula, wherein the atoms making up the other compound differ in theway they are oriented in space, but wherein the atoms in the othercompound are like the atoms in the given compound with respect to whichatoms are joined to which other atoms (e.g. an enantiomer, adiastereomer, or a geometric isomer). See for example, Morrison andBoyd, Organic Chemistry, 1983, 4th ed., Allyn and Bacon, Inc., Boston,Mass., p. 123.

“Substituted” refers to a group in which one or more hydrogen atoms areeach independently replaced with the same or different substituent(s).“Substituted” groups particularly refer to groups having 1 or moresubstituents, for instance from 1 to 5 substituents, and particularlyfrom 1 to 3 substituents, selected from the group consisting of acyl,acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl,alkoxycarbonylamino, amino, substituted amino, aminocarbonyl,aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, aralkyl, azido,carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl,imidate, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy,thioketo, thiol, alkylthio, (substituted alkyl)thio, arylthio,(substituted aryl)thio, alkyl-S(O)—, aryl-S(O)—, alkyl-S(O)₂— andaryl-S(O)₂. Typical substituents include, but are not limited to, —X,—R⁸ (with the proviso that R⁸ is not hydrogen), —O—, ═O, —OR⁸, —SR⁸,—S⁻, ═S, —NR⁸R⁹, ═NR⁸, —CX₃, —CF₃, —CN, —OCN, —SCN, —NO, —NO₂, ═N₂, —N₃,—S(O)₂O⁻, —S(O)₂OH, —S(O)₂R⁸, —OS(O₂)O⁻, —OS(O)₂R⁸, —P(O)(O—)₂,—P(O)(OR⁸)(O⁻), —OP(O)(OR⁸)(OR⁹), —C(O)R⁸, —C(S)R⁸, —C(O)OR⁸,—C(O)NR⁸R⁹, —C(O)O⁻, —C(S)OR⁸, —NR¹⁰C(O)NR⁸R⁹, —NR¹⁰C(S)NR⁸R⁹,—NR¹¹C(NR¹⁰)NR⁸R⁹ and —C(NR¹⁰)NR⁸R⁹, where each X is independently ahalogen.

“Substituted amino” includes those groups recited in the definition of“substituted” herein, and particularly refers to the group —N(R)₂ whereeach R is independently selected from the group consisting of hydrogen,alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,substituted alkynyl, aryl, cycloalkyl, substituted cycloalkyl, and whereboth R groups are joined to form an alkylene group.

“Thioalkoxy” refers to the group —S-alkyl.

“Thioaryloxy” refers to the group —S-aryl.

“Thioketo” refers to the group ═S.

“Thiol” refers to the group —SH.

“Uridine phosphorylase” refers in enzymology to a phosphorylase (EC2.4.2.3) that catalyzes the chemical reaction:uridine+phosphate→uracil+alpha-D-ribose 1-phosphate. The two substratesof this enzyme are uridine and phosphate, whereas its two products areuracil and alpha-D-ribose 1-phosphate. This enzyme belongs to the familyof glycosyltransferases, specifically the pentosyltransferases. Thesystematic name of this enzyme class is uridine:phosphatealpha-D-ribosyltransferase. Other names in common use include pyrimidinephosphorylase, UrdPase, UPH, and UPase. This enzyme participates inpyrimidine metabolism.

One having ordinary skill in the art will recognize that the maximumnumber of heteroatoms in a stable, chemically feasible heterocyclicring, whether it is aromatic or non aromatic, is determined by the sizeof the ring, the degree of unsaturation and the valence of theheteroatoms. In general, a heterocyclic ring may have one to fourheteroatoms so long as the heteroaromatic ring is chemically feasibleand stable.

DETAILED DESCRIPTION

Methods of using adjuvants to reduce the toxicity of methotrexate (MTX)in a host are provided. In the subject methods, an effective amount ofan MTX active agent is administered to the host in conjunction with theadministration of an MTX toxicity-reducing adjuvant of the presentinvention, where the MTX active agent and MTX toxicity-reducing adjuvantmay be administered either sequentially, in any order, simultaneously,or a combination thereof. Also provided are compositions for use inpracticing the subject methods, e.g., MTX pharmaceutical compositionshaving reduced toxicity and kits that include the same. The subjectmethods and compositions find use in a variety of differentapplications, including the treatment of a variety of different diseaseconditions.

Of particular interest is the use of anhydronucleosides as adjuvants toameliorate the toxic side-effects of MTX, as well as compositions forpracticing the subject methods and other applications.Anhydronucleosides are analogs of natural nucleosides, often finding useas intermediates in the synthesis of nucleoside derivatives. They arecharacterized by having, in addition to the N-glycoside linkage, acovalent linkage either directly or via bridging atoms between the 2′,3′, or 5′ carbons of the sugar and a carbon, oxygen or nitrogen atom(other than the nitrogen of the glycoside bond) of the base. Theanhydropyrimidines are characterized by a pyrimidine base that iscovalently linked either directly or via bridging atoms between the 2′,3′, or 5′ carbons of the sugar and a carbon, oxygen or nitrogen atom(other than the nitrogen of the glycoside bond) of the pyrimidine base.The MTX toxicity-reducing adjuvant 2,2′-anhydropyrimidine andderivatives thereof are of specific interest.

Before the present invention is described in greater detail, it is to beunderstood that this invention is not limited to particular embodimentsdescribed, as such may, of course, vary. It is also to be understoodthat the terminology used herein is for the purpose of describingparticular embodiments only, and is not intended to be limiting, sincethe scope of the present invention will be limited only by the appendedclaims.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range and any other stated or intervening value in thatstated range, is encompassed within the invention. The upper and lowerlimits of these smaller ranges may independently be included in thesmaller ranges and are also encompassed within the invention, subject toany specifically excluded limit in the stated range. Where the statedrange includes one or both of the limits, ranges excluding either orboth of those included limits are also included in the invention.

Certain ranges are presented herein with numerical values being precededby the term “about.” The term “about” is used herein to provide literalsupport for the exact number that it precedes, as well as a number thatis near to or approximately the number that the term precedes. Indetermining whether a number is near to or approximately a specificallyrecited number, the near or approximating unrecited number may be anumber which, in the context in which it is presented, provides thesubstantial equivalent of the specifically recited number.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can also beused in the practice or testing of the present invention, representativeillustrative methods and materials are now described.

All publications and patents cited in this specification are hereinincorporated by reference as if each individual publication or patentwere specifically and individually indicated to be incorporated byreference and are incorporated herein by reference to disclose anddescribe the methods and/or materials in connection with which thepublications are cited. The citation of any publication is for itsdisclosure prior to the filing date and should not be construed as anadmission that the present invention is not entitled to antedate suchpublication by virtue of prior invention. Further, the dates ofpublication provided may be different from the actual publication dateswhich may need to be independently confirmed.

It is noted that, as used herein and in the appended claims, thesingular forms “a”, “an”, and “the” include plural referents unless thecontext clearly dictates otherwise. It is further noted that the claimsmay be drafted to exclude any optional element. As such, this statementis intended to serve as antecedent basis for use of such exclusiveterminology as “solely,” “only” and the like in connection with therecitation of claim elements, or use of a “negative” limitation.

As will be apparent to those of skill in the art upon reading thisdisclosure, each of the individual embodiments described and illustratedherein has discrete components and features which may be readilyseparated from or combined with the features of any of the other severalembodiments without departing from the scope or spirit of the presentinvention. Any recited method can be carried out in the order of eventsrecited or in any other order which is logically possible.

In further describing the subject invention, the subject methods aredescribed first in greater detail, followed by a review of the variouscompositions, e.g., formulations and kits, that may find use in thesubject methods, as well as a discussion of various representativeapplications in which the subject methods and compositions find use.

Methods

As summarized above, the subject invention provides methods ofadministering an MTX active agent to a subject in need thereof, e.g.,for the treatment of a host suffering from disease or conditiontreatable by an MTX active agent (as described in greater detail below).An aspect of the subject methods is that the MTX active agent isadministered to the subject in combination with a MTX toxicity-reducingadjuvant. In certain embodiments, the MTX toxicity-reducing adjuvant isa 2,2′-anhydropyrimidine, such as a 2,2′-anhydrouridine oranalogue/derivative thereof. By “in combination with”, is meant that anamount of the MTX toxicity-reducing adjuvant is administered anywherefrom simultaneously to up to 5 hours or more, e.g., 10 hours, 15 hours,20 hours or more, prior to, or after, the MTX active agent. In certainembodiments, the MTX active agent and MTX toxicity reducing adjuvant areadministered sequentially, e.g., where the MTX active agent isadministered before or after the MTX toxicity-reducing adjuvant. In yetother embodiments, the MTX active agent and MTX toxicity-reducingadjuvant are administered simultaneously, e.g., where the MTX activeagent and MTX toxicity-reducing adjuvant are administered at the sametime as two separate formulations, or are combined into a singlecomposition, that is administered to the subject. Regardless of whetherthe MTX active agent and MTX toxicity-reducing adjuvant are administeredsequentially or simultaneously, as illustrated above, or any effectivevariation thereof, the agents are considered to be administered togetheror in combination for purposes of the present invention. Routes ofadministration of the two agents may vary, where representative routesof administration are described in greater detail below.

In the subject methods, an effective amount of an MTX active agent isadministered to a host in need thereof in combination with an effectiveamount of an MTX toxicity-reducing adjuvant. By “MTX active agent” ismeant methotrexate or an analogue/derivative thereof. MTX andanalogues/derivatives thereof which may be present in the subjectcompositions include, but are not limited to, those compounds describedin U.S. Pat. Nos. 2,512,572; 3,892,801; 3,989,703; 4,057,548; 4,067,867;4,079,056; 4,080,325; 4,136,101; 4,224,446; 4,306,064; 4,374,987;4,421,913; 4,767,859; 3,981,983; 4,043,759; 4,093,607; 4,279,992;4,376,767; 4,401,592; 4,489,065; 4,622,218; 4,625,014; 4,638,045;4,671,958; 4,699,784; 4,785,080; 4,816,395; 4,886,780; 4,918,165;4,925,662; 4,939,240; 4,983,586; 4,997,913; 5,024,998; 5,028,697;5,030,719; 5,057,313; 5,059,413; 5,082,928; 5,106,950; 5,108,987;4,106,488; 4,558,690; 4,662,359; 4,396,601; 4,497,796; 5,043,270;5,166,149; 5,292,731; 5,354,753; 5,382,582; 5,698,556; 5,728,692; and5,958,928; the disclosures of which are herein incorporated byreference.

MTX active agents of the present invention include MTX and anyanalogues/derivatives thereof whose toxicity is reduced whenadministered in conjunction with a toxicity-reducing adjuvant accordingto the subject invention. Whether or not a given MTX active agent issuitable for use according to the present invention can be readilydetermined using assays employed in the experimental section, below.Generally, an MTX active agent is suitable for use in the subjectmethods if its toxicity is reduced by 2 to 10-fold or more, such as by50-fold or more and sometimes by 100-fold or more, by the MTXtoxicity-reducing adjuvant as determined using the Drosophilamelanogaster assay described in the Experimental section, below. Incertain embodiments, the MTX active agent is one whose occurrence and/orintensity of observable toxic side-effects are reduced by the MTXtoxicity-reducing adjuvant as observed in the mouse assay described inthe experimental section below.

The phrase “MTX toxicity-reducing adjuvant” refers to an agent thatreduces toxicity of an MTX active agent. MTX toxicity-reducing adjuvantsof interest are those agents that reduce the toxicity of an MTX activeagent by 2 to 10-fold or more, such as by 50-fold or more and includingby 100-fold or more, as determined using the Drosophila melanogasterassay described in the Experimental section, below. In certainembodiments, the MTX toxicity-reducing adjuvants of interest are thosethat reduce the occurrence and/or intensity of observable toxicside-effects of a given MTX active agent, as observed in the mouse assaydescribed in the Experimental section below. Aspects oftoxicity-reducing adjuvants according to certain embodiments of theinvention are that the adjuvants do not substantially reduce, and incertain embodiments have no impact at all, on the cytotoxicity of theMTX active agent, e.g., as determined using the protocol described inthe Experimental Section below.

The MTX toxicity-reducing adjuvants of interest are2,2′-anhydropyrimidines and derivatives thereof. In some embodiments,the 2,2′-anhydropyrimidine or derivative thereof is a compound offormula (I):

or the pharmaceutically acceptable salts, solvates, hydrates, andprodrug forms thereof, and stereoisomers thereof;

wherein:

each R¹, R², R³ and R⁴ is independently selected from the groupconsisting of hydrogen, substituted or unsubstituted heteroatom,substituted or unsubstituted alkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, substituted or unsubstituted heteroaryl,substituted or unsubstituted aralkyl, hydroxyl, halogen, azido, amino,substituted amino, carbohydrate, nucleic acid, amino acid, peptide, dye,fluorophore and polypeptide.

In certain embodiments, the compound is of formula (I), R¹, R², R³ andR⁴ are independently hydrogen, hydroxyl, heteroatom, C₁-C₁₈ alkyl,C₁-C₁₈ substituted alkyl, C₁-C₁₈ alkenyl, C₁-C₁₈ acyl, amino,substituted amino, wherein the alkyl, alkenyl or acyl is linear orbranched, and optionally substituted with a hydroxyl, an ester and itsderivatives, a carboxyl and its derivatives, a cycloalkyl, aheterocycloalkyl, an aryl, a heteroaryl, an aralkyl, a heteroatom, andpossibly containing in chain or bridging heteroatoms such as nitrogen,oxygen and sulfur.

Examples of R¹ constituents of interest include, but are not limited to:hydrogen; hydroxyl; sulfyhydryl; halogen such as fluorine, chlorine,bromine or iodine, as well as pseudohalogen such as a loweralkylsulfonyl group of 1 to 5 carbons such as methyl-, ethyl-, propyl-,isopropyl-, butyl-, isobutyl-, tert-butyl-, and pentasulfonyl orarylsulfonyl such as benzene, p-toluene, p-nitrobenzenesulfonyl groups;lower alkyl containing 1 to 20 carbons such as methyl, ethyl, propyl,isopropyl, butyl, isobutyl, tert-butyl, pentyl and the like, includingsubstituted lower alkyl such as aminomethyl, hydroxymethyl, methoxy,ethyloxy, propyloxy, benzyloxy, imidate, alkylthio, (substitutedalkyl)thio, arylthio, (substituted aryl)thio and the like; lower alkenylcontaining 1 to 20 carbons such as vinyl and substituted vinyl, ethynyland substituted ethynyl, where the substituted vinyl or substitutedethynyl designates substitution of the β position of vinyl or ethynyl bya halogen such as bromine, chlorine, fluorine or iodine, or substitutionby an alkyl of 1 to 5 carbon atoms such as methyl, ethyl, propyl, butyl,pentyl and the like, or aralkyl such as benzyl, p-chlorobenzyl,p-nitrobenzyl and the like, or aryl such as phenyl, p-nitrophenyl,p-tolyl, p-anisyl, naphtyl and the like; lower alkanoyl (acyl groups)containing 1 to 20 carbons such as formyl, acetyl, propionyl,isopropionyl, butyryl, isobutyryl, tert-butyryl, valeryl, pivaloyl,caproyl, capryl, lauryl, myristyl, palmityl, stearyl, arachidyl,stilligyl, palmitoyl, oleyl, linolenyl, arachidonyl and the like; loweraryl containing 1 to 20 carbons such as phenyl, p-tolyl, p-chlorophenyl,p-aminophenyl, p-nitrophenyl, p-anisyl and the like; lower aroylcontaining 1 to 20 carbons such as benzoyl and naphthoyl, where thearomatic group may be additionally substituted by alkyl, alkoxy, halo,or nitro moieties such as p-tolnoyl, p-anisoyl, p-chlorobenzoyl,p-nitrobenzoyl or 2,4-dinitrobenzoyl, pentafluorobenzoyl and the like,or another aroyl such as benzyloxybenzoyl and the like; lower aralkylcontaining 1 to 20 carbons such as benzyl, benzhydryl, p-chlorobenzyl,m-chlorobenzyl, p-nitrobenzyl, benzyloxybenzyl, pentafluorobenzyl andthe like; amino or alkylamino containing 1 to 20 carbons such as amonoalkyl- or monoaralkylamino groups like methylamino, ethylamino,propylamino or benzylamino and the like, dialkylamino such asdimethylamino, diethylamino, dibenzylamino, pyrrolidino, piperidino ormolpholino and the like.

Thus in certain embodiments, R¹ is hydrogen, hydroxyl, sulfyhydryl,amino, substituted amino, hydroxymethyl, monomethoxy, halogen,pseudohalogen, or a lower hydrocarbon (which hydrocarbon can besubstituted or unsubstituted) containing from 1 to 20 atoms. In aparticular embodiment, R¹ is a lower hydrocarbon selected from alkyl,substituted alkyl, alkenyl, alkanoyl, aryl, aroyl, aralkyl, oralkylamino. In a particular embodiment, R¹ is a lower hydrocarbonsubstituted with alkoxy, substituted alkoxy, imidate, arylthio, or(substituted aryl)thio. In other embodiments, R¹ is a lower alkylselected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl,tert-butyl and pentyl. In other embodiments, R¹ is a lower alkenylselected from vinyl, substituted vinyl, ethynyl, or substituted ethynyl.In other embodiments, R¹ is a lower alkanoyl selected from formyl,acetyl, propionyl, isopropionyl, butyryl, isobutyryl, tert-butyryl,valeryl, pivaloyl, caproyl, capryl, lauryl, myristyl, palmityl, stearyl,arachidyl, stilligyl, palmitoyl, oleyl, linolenyl, and arachidonyl. Inother embodiments, R¹ is lower aryl selected from phenyl, p-tolyl,p-chlorophenyl, p-aminophenyl, p-nitrophenyl, p-anisyl. In yet otherembodiments, R¹ is a lower aroyl selected from benzoyl and naphthoyl. Inother embodiments, R¹ is a lower aralkyl selected from benzyl,benzhydryl, p-chlorobenzyl, m-chlorobenzyl, p-nitrobenzyl,benzyloxybenzyl, or pentafluorobenzyl. In certain other embodiments, R¹is a lower alkylamino is selected from monoalkylamino, monoaralkylamino,dialkylamino, diaralkylamino, and benzylamino.

Compounds of interest include, but are not limited to, those of formula(I) where R¹ is selected from hydrogen, fluorine, trifluoromethyl,methyl, ethyl, propyl, butyl, isopropyl, isobutyl, acetyl, propionyl,butyryl, 2-bromovinyl, phenyl, benzyl, benzoyl, benzyloxybenzyl,benzylamino, alkyloxyalkyl, benzyloxyalkyl, imidatealkyl, arylthio, and(substituted aryl)thio. Thus in certain embodiments, the compound is offormula (I), and R¹ is H, F, CF₃, CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH,(CH₃)₂CH₂CH₂, CH₃(O)CCH₂, CH₃(O)CCH₂CH₂, Br—CH═CH, phenyl, benzyl,benzoyl, benzyloxybenzyl, benzyl-NH—, CH₃CH₂OCH₂, benzyl-O—CH₂, CH₃OCH₂,CH₃C(NH)—O—CH₂, or CH₃-phenyl-O—CH₂.

Examples of R² constituents of interest include, but are not limited to:hydrogen; hydroxyl; sulfyhydryl; halogen such as fluorine, chlorine,bromine or iodine, as well as pseudohalogen such as a loweralkylsulfonyl group of 1 to 5 carbons such as methyl-, ethyl-, propyl-,isopropyl-, butyl-, isobutyl-, tert-butyl-, and pentasulfonyl orarylsulfonyl such as benzene, p-toluene, p-nitrobenzenesulfonyl groups;lower alkyl containing 1 to 20 carbons such as methyl, ethyl, propyl,isopropyl, butyl, isobutyl, tert-butyl, pentyl and the like, includingsubstituted lower alkyl such as aminomethyl, hydroxymethyl, methoxy,ethyloxy, propyloxy, and the like; lower alkenyl containing 1 to 20carbons such as vinyl and substituted vinyl, ethynyl and substitutedethynyl, where the substituted vinyl or substituted ethynyl designatessubstitution of the R position of vinyl or ethynyl by a halogen such asbromine, chlorine, fluorine or iodine, or substitution by an alkyl of 1to 5 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl and thelike, or aralkyl such as benzyl, p-chlorobenzyl, p-nitrobenzyl and thelike, or aryl such as phenyl, p-nitrophenyl, p-tolyl, p-anisyl, naphtyland the like; lower alkanoyl (acyl groups) and esters thereof of a mainchain containing 1 to 20 carbons such as formyl, acetyl, propionyl,isopropionyl, butyryl, isobutyryl, tert-butyryl, valeryl, pivaloyl,caproyl, capryl, lauryl, myristyl, palmityl, stearyl, arachidyl,stilligyl, palmitoyl, oleyl, linolenyl, arachidonyl and the like; loweraryl containing 1 to 20 carbons such as phenyl, p-tolyl, p-chlorophenyl,p-aminophenyl, p-nitrophenyl, p-anisyl and the like; lower aroylcontaining 1 to 20 carbons such as benzoyl and naphthoyl, where thearomatic group may be additionally substituted by alkyl, alkoxy, halo,or nitro moieties such as p-tolnoyl, p-anisoyl, p-chlorobenzoyl,p-nitrobenzoyl or 2,4-dinitrobenzoyl, pentafluorobenzoyl and the like,or another aroyl such as benzyloxybenzoyl and the like; lower aralkylcontaining 1 to 20 carbons such as benzyl, benzhydryl, p-chlorobenzyl,m-chlorobenzyl, p-nitrobenzyl, benzyloxybenzyl, pentafluorobenzyl andthe like; lower aryloxy containing 1 to 20 carbons such as phenyloxy(i.e., O-phenyl), benzyloxy (i.e., O-benzyl), benzhydryloxy (i.e.,O-benzylhydryl), p-chlorobenzyloxy (i.e., O-(p-chlorobenzyl)),m-chlorobenzyloxy (i.e., O-(m-chlorobenzyl)), p-nitrobenzyloxy (i.e.,O-(p-nitrobenzyl)), (4-benzyloxybenzyl)-oxy (i.e., O-benzyloxybenzyl),or pentafluorobenzyloxy (i.e., O-pentafluorobenzyl); esters of aryloxys,such as lower aroyloxy (i.e., O-aroyl) containing 1 to 20 carbons suchas benzoyloxy (i.e., O-benzoyl), diphenylacetyloxy (i.e.,O-diphenylacetyl), p-chlorobenzoyloxy (i.e., O-(p-chlorobenzoyl)),m-chlorobenzoyloxy (i.e., O-(m-chlorobenzoyl)), p-nitrobenzoyloxy (i.e.,O-(p-nitrobenzoyl)), (4-benzyloxybenzoyl)-oxy (i.e.,O-benzyloxybenzoyl), or pentafluorobenzoyloxy (i.e.,O-pentafluorobenzoyl); amino or alkylamino containing 1 to 20 carbonssuch as a monoalkyl- or monoaralkylamino groups like methylamino,ethylamino, propylamino or benzylamino and the like, dialkylamino suchas dimethylamino, diethylamino, dibenzylamino, pyrrolidino, piperidinoor molpholino and the like.

Thus in certain embodiments, R² is hydrogen, hydroxyl, sulfyhydryl,amino, hydroxymethyl, monomethoxy, halogen, pseudohalogen, or a lowerhydrocarbon (which hydrocarbon can be substituted or unsubstituted)containing from 1 to 20 atoms, and esters thereof. In a particularembodiment, R² is a lower hydrocarbon selected from alkyl, alkenyl,alkanoyl, aryl, aroyl, aryloxy, aroyloxy, aralkyl, or alkylamino. Inother embodiments, R² is a lower alkyl selected from methyl, ethyl,propyl, isopropyl, butyl, isobutyl, tert-butyl and pentyl. In otherembodiments, R² is a lower alkenyl selected from vinyl, substitutedvinyl, ethynyl, or substituted ethynyl. In other embodiments, R² is alower alkanoyl selected from formyl, acetyl, propionyl, isopropionyl,butyryl, isobutyryl, tert-butyryl, valeryl, pivaloyl, caproyl, capryl,lauryl, myristyl, palmityl, stearyl, arachidyl, stilligyl, palmitoyl,oleyl, linolenyl, and arachidonyl. In other embodiments, R² is loweraryl selected from phenyl, p-tolyl, p-chlorophenyl, p-aminophenyl,p-nitrophenyl, p-anisyl. In yet other embodiments, R² is a lower aroylselected from benzoyl and naphthoyl. In other embodiments, R² is a loweraralkyl selected from benzyl, benzhydryl, p-chlorobenzyl,m-chlorobenzyl, p-nitrobenzyl, benzyloxybenzyl, or pentafluorobenzyl. Inother embodiments, R² is a lower aryloxy selected from phenyloxy,benzyloxy, benzhydryloxy, p-chlorobenzyloxy, m-chlorobenzyloxy,p-nitrobenzyloxy, (4-benzyloxybenzyl)-oxy, or pentafluorobenzyloxy. Inother embodiments, R² is a lower aroyloxy selected from benzoyloxy,diphenylacetyloxy, p-chlorobenzoyloxy, m-chlorobenzoyloxy,p-nitrobenzoyloxy, (4-benzyloxybenzoyl)-oxy, or pentafluorobenzoyloxy.In certain other embodiments, R² is a lower alkylamino is selected frommonoalkylamino, monoaralkylamino, dialkylamino, and diaralkylamino. Thusin certain embodiments, R² can not only be hydrogen or hydroxyl, butalso an O-acyl, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, O-alkyl,O-alkylene, O-alkynyl, O-aralkyl, O-aryl, O-aryloxy, O-carbohydrate,O-cycloalkenyl, O-cycloalkyl, O-heterocycloalkyl, O-heteroaryl. Inaddition, an S can substitute for the O.

Compounds of interest include, but are not limited to, those of formula(I) where R² is selected from hydrogen, fluorine, trifluoromethyl,methyl, ethyl, propyl, butyl, isopropyl, isobutyl, acetyl, propionyl,butyryl, 2-bromovinyl, phenyl, phenyloxy, benzyl, benzoyl, benzoyloxyand benzyloxybenzyl. Thus in certain embodiments, the compound is offormula (I), and R² is H, F, CF₃, CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH,(CH₃)₂CH₂CH₂, CH₃(O)CCH₂, CH₃(O)CCH₂CH₂, Br—CH═CH, phenyl, phenyloxy,benzyl, benzoyl, benzoyloxy, or benzyloxybenzyl.

In specific embodiments of interest, the compound is of formula (I), andR² is hydrogen, hydroxyl, or an O-linked substituent. This includescompounds of formula (I), where R² is H, OH or C₆H₅C(O)O.

Examples of R³ of interest include, but are not limited to: hydrogen;hydroxyl; azido; sulfyhydryl; halogen; pseudohalogen; lower alkylcontaining 1 to 20 carbons such as methyl, ethyl, propyl, isopropyl,butyl, isobutyl, tert-butyl, pentyl and the like, including asubstituted lower alkyl such as aminomethyl, hydroxymethyl, methoxy,ethyloxy, propyloxy, and the like; lower alkanoyl (acyl) includingesters thereof of a main chain of 1 to 20 carbon atoms such as formyl,acetyl, propionyl, isopropionyl, butyryl, isobutyryl, tert-butyryl,valeryl, pivaloyl, caproyl, capryl, lauryl, myristyl, palmityl, stearyl,arachidyl, stilligyl, palmitoyl, oleyl, linolenyl, arachidonyl and thelike; lower aryl such as phenyl, p-nitrophenyl, p-tolyl, p-anisyl,naphtyl and the like; lower aroyl (acyl radical of an aromatic acid) of1 to 20 carbons such as benzoyl and naphthoyl, where the aromatic groupmay be additionally substituted by alkyl, alkoxy, halo, or nitromoieties such as p-tolnoyl, p-anisoyl, p-chlorobenzoyl, p-nitrobenzoylor 2,4-dinitrobenzoyl, pentafluorobenzoyl and the like; lower aryloxy of1 to 20 carbons such as phenyloxy, benzyloxy, benzhydryloxy,p-chlorobenzyloxy, m-chlorobenzyloxy, p-nitrobenzyloxy,(4-benzyloxybenzyl)-oxy, or pentafluorobenzyloxy and the like; as wellas esters of aryloxys, such as lower aroyloxy (O-aroyls) of 1 to 20carbons such as benzoyloxy, di phenylacetyloxy, p-chlorobenzoyloxy,m-chlorobenzoyloxy, p-nitrobenzoyloxy, (4-benzyloxybenzoyl)-oxy, orpentafluorobenzoyloxy and the like. R³ may also be adamantoyl, orsubstituted adamantoyl.

Thus in certain embodiments, R³ is hydrogen, hydroxyl, azido,sulfyhydryl, hydroxymethyl, halogen, or pseudohalogen. In otherembodiments, R³ is a lower hydrocarbon selected from alkyl, alkanoyl,aryl, aroyl, aryloxy, aroyloxy, or aralkyl. In other embodiments, R³ isa lower alkyl selected from methyl, ethyl, propyl, isopropyl, butyl,isobutyl, tert-butyl and pentyl. In other embodiments, R³ is a loweralkanoyl selected from formyl, acetyl, propionyl, isopropionyl, butyryl,isobutyryl, tert-butyryl, valeryl, pivaloyl, caproyl, capryl, lauryl,myristyl, palmityl, stearyl, arachidyl, stilligyl, palmitoyl, oleyl,linolenyl, and arachidonyl. In other embodiments, R³ is a lower arylselected from phenyl, p-tolyl, p-chlorophenyl, p-aminophenyl,p-nitrophenyl, p-anisyl and the like. In other embodiments, R³ is alower aroyl selected from benzoyl and naphthoyl. In yet other certainembodiments, R³ is a lower aralkyl selected from benzyl, benzhydryl,p-chlorobenzyl, m-chlorobenzyl, p-nitrobenzyl, benzyloxybenzyl, orpentafluorobenzyl. In other embodiments, R³ is a lower aryloxy selectedfrom phenyloxy, benzyloxy, benzhydryloxy, p-chlorobenzyloxy,m-chlorobenzyloxy, p-nitrobenzyloxy, (4-benzyloxybenzyl)-oxy, orpentafluorobenzyloxy. In other embodiments, R³ is a lower aroyloxyselected from benzoyloxy, diphenylacetyloxy, p-chlorobenzoyloxy,m-chlorobenzoyloxy, p-nitrobenzoyloxy, (4-benzyloxybenzoyl)-oxy, orpentafluorobenzoyloxy. Thus in certain embodiments, R³ can not only behydrogen or hydroxyl, but also an O-acyl, alkoxy, alkoxycarbonyl,alkoxycarbonylamino, O-alkyl, O-alkylene, O-alkynyl, O-aralkyl, O-aryl,O-aryloxy, O-carbohydrate, O-cycloalkenyl, O-cycloalkyl,O-heterocycloalkyl, O-heteroaryl. In addition, an S can substitute forthe O.

Compounds of interest are those of formula (I) where R³ is hydrogen,hydroxyl, halogen, azido, or an O-linked substituent. This includescompounds of formula (I) where R³ is selected from hydrogen, hydroxyl,n-butoxy, isobutyloxy, t-butyloxy, phenyloxy, benzyloxy, benzoyloxy, andpentafluorobenzoyloxy. Thus in certain embodiments, the compound is offormula (I), and R³ is selected from H, OH, CH₃CH₂CH₂CH₂O,(CH₃)₂CH₂CH₂O, (CH₃)₃CO, C₆H₅O, benzoyloxy, and pentafluorobenzoyloxy.

In specific embodiments of interest, the compound is of formula (I),where R³ is H, OH, F, Cl, Br, I, N₃, or C₆H₅C(O)O. Of special interestis a compound of formula (I), where R³ is OH, or O-acyl (for example, anester such as C₆H₅C(O)O).

Examples of R⁴ include, but are not limited to: hydrogen; hydroxyl;sulfhydryl; halogen such as fluorine, chlorine, bromine or iodine; aminoor lower alkylamino. R⁴ also is exemplified by lower alkyl, with acylgroups which may be lower alkanoyl groups of 1 to 7 carbon atoms such asformyl, acetyl, propionyl, isopropionyl, butyryl, isobutyryl,tert-butyryl and the like, and esters thereof. Thus, R⁴ can also bearoyl (and esters thereof such as O-linked aroyls, i.e., O-arolys orarolyoxy) such as benzoyl and naphthoyl wherein the aromatic group maybe additionally substituted by alkyl, alkoxy, halo, or nitro moietiessuch as p-tolnoyl, p-anisoyl, p-chlorobenzoyl, p-nitrobenzoyl or2,4-dinitrobenzoyl and the like. Accordingly, in certain embodiments, R⁴can not only be hydrogen or hydroxyl, but also an O-acyl, alkoxy,alkoxycarbonyl, alkoxycarbonylamino, O-alkyl, O-alkylene, O-alkynyl,O-aralkyl, O-aryl, O-aryloxy, O-carbohydrate, O-cycloalkenyl,O-cycloalkyl, O-heterocycloalkyl, O-heteroaryl. In addition, an S cansubstitute for the O.

Thus in certain embodiments, R⁴ is hydrogen; hydroxyl; sulfhydryl;halogen, amino aminomethyl, or aminodimethyl. In other embodiments, R⁴is a lower alkyl, acyl, aroyl, or aroyloxy. This includes a specificembodiment, where the compound of formula (I) is one where R⁴ ishydrogen, flourine, hydroxyl, amino, aminomethyl, aminodimethyl,t-butyloxy, phenyloxy or benzoyloxy (for example, a compound of formula(I), where R⁴ is H, F, OH, NH₂, NHCH₃, N(CH₃)₂, (CH₃)₃CO, C₆H₅O orC₆H₅C(O)O).

Compounds of particular interest are those of formula (I) where R⁴ ishydrogen, hydroxyl, or an O-linked substituent. In specific embodiments,the compound is of formula (I), where R⁴ is H, OH or C₆H₅C(O)O. Ofspecial interest is a compound of formula (I), where R⁴ is OH, or O-acyl(for example, an ester such as C₆H₅C(O)O).

Of interest are compounds of formula (I) where: R¹ is H, F, CF₃, CH₃,CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH, (CH₃)₂CH₂CH₂, CH₃(O)CCH₂, CH₃(O)CCH₂CH₂,Br—CH═CH, phenyl, benzyl, benzoyl, or benzyloxybenzyl, R² is H, OH, F,CF₃, CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH, (CH₃)₂CH₂CH₂, CH₃(O)CCH₂,CH₃(O)CCH₂CH₂, Br—CH═CH, phenyl, phenyloxy, benzyl, benzoyl, benzoyloxy,or benzyloxybenzyl, and where R³ and R⁴ are each hydroxyl. These includethe compounds: 2,2′-anhydrouridine; 2,2′-anhydro-5-fluorouridine;2,2′-anhydro-5-trifluoromethyluridine; 2,2′-anhydro-5-methyluridine;2,2′-anhydro-5-ethyluridine; 2,2′-anhydro-5-propyluridine;2,2′-anhydro-5-isopropyluridine; 2,2′-anhydro-5-isobutyluridine;2,2′-anhydro-5-methylacyluridine; 2,2′-anhydro-5-propylacyluridine;2,2′-anhydro-5-(2-bromovinyl)-uridine; 2,2′-anhydro-5-phenylluridine;2,2′-anhydro-5-benzyluridine; 2,2′-anhydro-5-benzyoluridine; and2,2′-anhydro-5-(benzyloxybenzyl)-uridine. Of special interest is2,2′-anhydro-5-methyluridine, or the pharmaceutically acceptable salts,solvates, hydrates, and prodrug forms thereof, and stereoisomersthereof.

Additional compounds of interest are compounds of formula (I) where: R¹is H, F, CF₃, CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH, (CH₃)₂CH₂CH₂,CH₃(O)CCH₂, CH₃(O)CCH₂CH₂, Br—CH═CH, phenyl, benzyl, benzoyl, orbenzyloxybenzyl, R² is H, OH, F, CF₃, CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH,(CH₃)₂CH₂CH₂, CH₃(O)CCH₂, CH₃(O)CCH₂CH₂, Br—CH═CH, phenyl, phenyloxy,benzyl, benzyloxy, benzoyl, benzoyloxy, or benzyloxybenzyl, and where R³is hydroxyl, and R⁴ is benzoyloxy. These include the compounds:3′-O-benzoyl-2,2′-anhydrouridine;3′-O-benzoyl-2,2′-anhydro-5-fluorouridine;3′-O-benzoyl-2,2′-anhydro-5-trifluoromethyluridine;3′-O-benzoyl-2,2′-anhydro-5-methyluridine;3′-O-benzoyl-2,2′-anhydro-5-ethyluridine;3′-O-benzoyl-2,2′-anhydro-5-propyluridine;3′-O-benzoyl-2,2′-anhydro-5-isopropyluridine;3′-O-benzoyl-2,2′-O-anhydro-5-isobutyluridine;3′-O-benzoyl-2,2′-anhydro-5-methylacyluridine;3′-O-benzoyl-2,2′-anhydro-5-propylacyluridine;3′-O-benzoyl-2,2′-anhydro-5-(2-bromovinyl)-uridine;3′-O-benzoyl-2,2′-anhydro-5-phenylluridine;3′-O-benzoyl-2,2′-anhydro-5-benzyluridine;3′-O-benzoyl-2,2′-anhydro-5-benzyoluridine; and3′-O-benzoyl-2,2′-anhydro-5-(benzyloxybenzyl)-uridine. Of specificinterest is 3′-O-benzoyl-2,2′-anhydro-5-methyluridine, or thepharmaceutically acceptable salts, solvates, hydrates, and prodrug formsthereof, and stereoisomers thereof.

Also of interest are compounds of formula (I) where: R¹ is H, F, CF₃,CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH, (CH₃)₂CH₂CH₂, CH₃(O)CCH₂,CH₃(O)CCH₂CH₂, Br—CH═CH, phenyl, benzyl, benzoyl, or benzyloxybenzyl, R²is H, OH, F, CF₃, CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH, (CH₃)₂CH₂CH₂,CH₃(O)CCH₂, CH₃(O)CCH₂CH₂, Br—CH═CH, phenyl, phenyloxy, benzyl,benzyloxy, benzoyl, benzoyloxy, or benzyloxybenzyl, and where R³ isbenzoyloxy, and R⁴ is hydroxyl. These include the compounds:5′-O-benzoyl-2,2′-anhydrouridine;5′-O-benzoyl-2,2′-anhydro-5-fluorouridine;5′-O-benzoyl-2,2′-anhydro-5-trifluoromethyluridine;5′-O-benzoyl-2,2′-anhydro-5-methyluridine;5′-O-benzoyl-2,2′-anhydro-5-ethyluridine;5′-O-benzoyl-2,2′-anhydro-5-propyluridine;5′-O-benzoyl-2,2′-anhydro-5-isopropyluridine;5′-O-benzoyl-2,2′-O-anhydro-5-isobutyl uridine;5′-O-benzoyl-2,2′-anhydro-5-methylacyluridine;5′-O-benzoyl-2,2′-anhydro-5-propylacyluridine;5′-O-benzoyl-2,2′-anhydro-5-(2-bromovinyl)-uridine;5′-O-benzoyl-2,2′-anhydro-5-phenylluridine;5′-O-benzoyl-2,2′-anhydro-5-benzyluridine;5′-O-benzoyl-2,2′-anhydro-5-benzyoluridine; and5′-O-benzoyl-2,2′-anhydro-5-(benzyloxybenzyl)-uridine. Of specificinterest is 5′-O-benzoyl-2,2′-anhydro-5-methyluridine, or thepharmaceutically acceptable salts, solvates, hydrates, and prodrug formsthereof, and stereoisomers thereof.

The 2,2′-anhydropyrimidine compounds of the invention may be incompositions that contain single stereoisomers, mixtures ofstereoisomers, as well various derivatives thereof that can occur asequilibrium mixtures of tautomers. For instance, 2,2′-anhydropyrimidinesaccording to formula (I) include four stereo centers with respect to thefurano ring, which includes the α and β anomers, and the L or D mirrorimage configurations. Examples of stereoisomers of the2,2′-anhydropyrimidine compounds of the invention are the β-D-isomer,β-L-isomer, α-D-isomer, and α-L-isomer, as well as tautomers andmixtures including α,β-D-isomers, α,β-L-isomers, α-DL-isomers, andβ-DL-isomers. Thus in one embodiment, compositions are provided thatconsists essentially of a stereoisomer of a 2,2′-anhydropyrimidine thatis a β-D-isomer, β-L-isomer, α-D-isomer, or an α-L-isomer. Stereoisomersexhibiting improved activity on a molar basis or improved specificitywith respect to interfering with MTX efficacy are of special interest.

Stereoisomers of particular interest include:2,2′-anhydro-1-(β-D-arabinofuranosyl)uracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-fluorouracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-trifluoromethyluracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyluracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-ethyluracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-n-propyluracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-isopropyluracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-isobutyluracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyacyluracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-propylacyluracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-(2-bromovinyl)uracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-phenyluracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-benzyluracil;2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-benzyoluracil; and2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-(3-benzyoxybenzyl)uracil.Further stereoisomers of interest include:3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)uracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-fluororacil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-trifluoromethyluracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyluracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-ethyluracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-n-propyluracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-isopropyluracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-isobutyluracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyacyluracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-propylacyluracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-(2-bromovinyl)uracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-phenyluracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-benzyluracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-benzyoluracil; and3′-O-benzoyl-2,2′-anhydro-1-((3-D-arabinofuranosyl)-5-(3-benzyoxybenzyl)uracil.Additional stereoisomers of interest include:5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)uracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-fluorouracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-trifluoromethyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-ethyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-n-propyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-isopropyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-isobutyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyacyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-propylacyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-(2-bromovinyl)uracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-phenyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-benzyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-benzyoluracil; and5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-(3-benzyoxybenzyl)uracil.

Examples of other analogs or derivatives of the 2,2′-anhydropyrimidinesof the invention, and stereoisomers thereof include:3′-O-acetyl-2,2′-anhydro-5-propyluridine(3′-O-acetyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-propyl uracil); and3′-O-acetyl-2,2′-anhydro-5-isopropyluridine(3′-O-acetyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-isopropyluracil);as well as the 2,2′-anhydrocytidines, and analogs and derivativesthereof, of which the stereoisomer2,2′-anhydro-1-(β-D-arabinofuranosyl)cytosine is one example.

As noted above, stereoisomers and the various 2,2′-anhydropyrimidines ofparticular interest are those which exhibit improved activity on a molarbasis, or improved specificity with respect to not interfering with MTXefficacy. Such compounds can be readily selected for this purpose bycomparing against a matrix of compounds of particular interest, such asthose illustrated in Table 1 (where the compound is of formula (I)).

TABLE 1 The compound is of formula (I) Compound Stereoisomer R¹ R² R³ R⁴I-a β-D-isomer H H OH OH I-b β-D-isomer CH₃ H OH OH I-c β-D-isomerCH₃CH₂ H OH OH I-d β-D-isomer CH₃CH₂CH H OH OH I-e β-D-isomer BrCH═CH HOH OH I-f β-D-isomer C₆H₅CH₂ H OH OH I-g β-D-isomer H H C₆H₅C(O)O OH I-hβ-D-isomer CH₃ H C₆H₅C(O)O OH I-i β-D-isomer CH₃CH₂ H C₆H₅C(O)O OH I-jβ-D-isomer CH₃CH₂CH H C₆H₅C(O)O OH I-k β-D-isomer BrCH═CH H C₆H₅C(O)O OHI-l β-D-isomer C₆H₅CH₂ H C₆H₅C(O)O OH I-m β-D-isomer F—C₆H₅CH₂ H OH OHI-n β-D-isomer NO₂—C₆H₅CH₂ H OH OH I-o β-D-isomer NH₂—C₆H₅CH₂ H OH OHI-p β-D-isomer Cl—C₆H₅CH₂ H OH OH I-q β-D-isomer Alkyl-C₆H₅CH₂ H OH OHI-r β-D-isomer Methoxy-C₆H₅CH₂ H OH OH I-s β-D-isomer Thiol-C₆H₅CH₂ H OHOH I-t β-D-isomer F—C₆H₅CH₂ H C₆H₅C(O)O OH I-u β-D-isomer NO₂—C₆H₅CH₂ HC₆H₅C(O)O OH I-v β-D-isomer NH₂—C₆H₅CH₂ H C₆H₅C(O)O OH I-w β-D-isomerCl—C₆H₅CH₂ H C₆H₅C(O)O OH I-x β-D-isomer Alkyl-C₆H₅CH₂ H C₆H₅C(O)O OHI-y β-D-isomer Methoxy-C₆H₅CH₂ H C₆H₅C(O)O OH I-z β-D-isomerThiol-C₆H₅CH₂ H C₆H₅C(O)O OH I-a′ β-D-isomer H OH H OH I-b′ β-D-isomerCH₃ OH H OH I-c′ β-D-isomer CH₃CH₂ OH H OH I-d′ β-D-isomer CH₃CH₂CH OH HOH I-e′ β-D-isomer BrCH═CH OH H OH I-f′ β-D-isomer C₆H₅CH₂ OH H OH I-g′β-D-isomer H C₆H₅C(O)O H OH I-h′ β-D-isomer CH₃ C₆H₅C(O)O H OH I-I′β-D-isomer CH₃CH₂ C₆H₅C(O)O H OH I-j′ β-D-isomer CH₃CH₂CH C₆H₅C(O)O H OHI-k′ β-D-isomer BrCH═CH C₆H₅C(O)O H OH I-l′ β-D-isomer C₆H₅CH₂ C₆H₅C(O)OH OH I-m′ β-D-isomer F—C₆H₅CH₂ OH H OH I-n′ β-D-isomer NO₂—C₆H₅CH₂ OH HOH I-o′ β-D-isomer NH₂—C₆H₅CH₂ OH H OH I-p′ β-D-isomer Cl—C₆H₅CH₂ OH HOH I-q′ β-D-isomer Alkyl-C₆H₅CH₂ OH H OH I-r′ β-D-isomer Methoxy-C₆H₅CH₂OH H OH I-s′ β-D-isomer Thiol-C₆H₅CH₂ OH H OH I-t′ β-D-isomer F—C₆H₅CH₂C₆H₅C(O)O H OH I-u′ β-D-isomer NO₂—C₆H₅CH₂ C₆H₅C(O)O H OH I-v′β-D-isomer NH₂—C₆H₅CH₂ C₆H₅C(O)O H OH I-w′ β-D-isomer Cl—C₆H₅CH₂C₆H₅C(O)O H OH I-x′ β-D-isomer Alkyl-C₆H₅CH₂ C₆H₅C(O)O H OH I-y′β-D-isomer Methoxy-C₆H₅CH₂ C₆H₅C(O)O H OH I-z′ β-D-isomer Thiol-C₆H₅CH₂C₆H₅C(O)O H OH

As mentioned above, the compounds in Table I are illustrative but notlimiting. For example, R⁴ can be not only hydroxyl, but also an O-acyl,alkoxy, alkoxycarbonyl, alkoxycarbonylamino, O-alkyl, O-alkylene,O-alkynyl, O-aralkyl, O-aryl, O-aryloxy, O-carbohydrate, O-cycloalkenyl,O-cycloalkyl, O-heterocycloalkyl, O-heteroaryl. In addition, an S cansubstitute for the O and other combinations of the structural elementssuch as described herein, as well as other streochemical orientations,are also possible.

In certain embodiments, acyl derivatives of the 2,2′-anyhydropyrimidinesof formula (I) are of interest. Thus, compounds of formula (I) includethose in which R¹, R², R³ and R⁴ are as defined above, wherein at leastone of R², R³ and R⁴ is an acyl derivative. By “acyl derivative” isintended a derivative of a 2,2′-anyhydropyrimidine of formula (I) inwhich at least one of R², R³ and R⁴ is a substantially nontoxic organicacyl substituent obtainable from a carboxylic acid that is attached to ahydroxyl group on the ribose or pyrimidine ring of formula (I) throughan ester linkage.

Acyl derivatives of a 2,2′-anyhydropyrimidine compound of formula (I)include those in which R¹ is as defined above, and each R², R³ and R⁴ isindependently hydrogen, hydroxyl or an acyl radical, with the provisothat at least one of R², R³ and R⁴ is not hydrogen. In anotherembodiment, the acyl derivative of a 2,2′-anyhydropyrimidine is acompound of formula (I) in which R¹ and R² are as defined above, withthe proviso that R² is other than hydrogen, and each R³ and R⁴ isindependently hydroxyl or an acyl radical. In one embodiment, the acylderivative of a 2,2′-anyhydropyrimidine is a compound of formula (I) inwhich R¹ is as defined above, R² is hydrogen, and each R³ and R⁴ isindependently hydroxyl or an acyl radical. Of particular interest, is anacyl derivative of a 2,2′-anyhydropyrimidine compound of formula (I),wherein R¹ is methyl, R² is hydrogen, and each R³ and R⁴ isindependently hydroxyl or an acyl radical. Also of interest is an acylderivative of a 2,2′-anyhydropyrimidine compound of formula (I), whereinR¹ is methyl, R² is hydrogen, and each R³ and R⁴ is an acyl radical.

In general, the ester linkage(s) of an acyl derivative of formula (I)are cleavable under physiological conditions, either in vitro, such asin a cell-based system, and/or in vivo, such as through metabolism in abody. Thus in certain embodiments, the acyl radical is a radical of ametabolite. Such acyl substituents include, but are not limited to,those derived from acetic acid, fatty acids, amino acids, lipoic acid,glycolic acid, lactic acid, enolpyruvic acid, pyruvic acid, orotic acid,acetoacetic acid, beta-hydroxybutyric acid, creatinic acid, succinicacid, fumaric acid, adipic acid, benzoic acid and p-aminobenzoic acid.Particular acyl substituents of interest are compounds which arenormally present in the body, either as dietary constituents or asintermediary metabolites, and which are essentially nontoxic whencleaved from the 2,2′-anyhydropyrimidine compound of interest in vivo.

Of particular interest are compositions comprising a3′-O-acyl-2,2′-anhydropyrimidine or derivative thereof. For example,acyl derivatives of interest are those that include a2,2′-anyhydropyrimidine compound of formula (I), where each R¹, R² andR³ is independently selected from selected from hydrogen, hydroxyl,sulfyhydryl, amino, hydroxymethyl, methoxy, halogen, pseudohalogen, anda substituted or unsubstituted lower hydrocarbon containing 1 to 20carbons, such as a lower hydrocarbon selected from alkyl, alkenyl,alkanoyl, aryl, aroyl, aralkyl and alkylamino, and esters thereof, andwhere R⁴ is an O-acyl radical.

In certain embodiments, the acyl derivatives include a2,2′-anyhydropyrimidine compound of formula (I), where R⁴ is an O-acylradical, and where the O-acyl radical comprises 1 to 10 carbon atoms,such as an O-acyl radical selected from aroyloxy, aralkoyloxy,heteroaroyloxy, and cycloalkoyloxy.

Accordingly, acyl derivatives of a 2,2′-anyhydropyrimidine compound offormula (I) include 3′-O-acyl-2,2′-anyhdropyrimidines,5′-O-acyl-2,2′-anyhdropyrimidines, 3′,5′-O-acyl-2,2′-anyhdropyrimidines,and derivatives thereof. For example, 3′-O-acyl-2,2′-anhydropyrimidinesor derivatives thereof include 3′-O-aroyl-2,2′-anhydropyrimidines, suchas a 3′-O-aroyl-2,2′-anhydrouridine or derivative thereof. An example ofparticular interest is 3′-O-benzoyl-2,2′-anhydrouridine or derivativethereof, such as 3′-O-benzoyl-2,2′-anhydro-5-methyluridine. Also ofinterest is a compound in which the3′-O-benzoyl-2,2′-anhydro-5-methyluridine is the stereoisomer3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyluracil.

In some embodiments, acyl derivatives of a 2,2′-anyhydropyrimidinecompound of formula (I) include those where: R¹ is H, F, CF₃, CH₃,CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH, (CH₃)₂CH₂CH₂, CH₃(O)CCH₂, CH₃(O)CCH₂CH₂,Br—CH═CH, phenyl, benzyl, benzoyl, or benzyloxybenzyl, R² is H, OH, F,CF₃, CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH, (CH₃)₂CH₂CH₂, CH₃(O)CCH₂,CH₃(O)CCH₂CH₂, Br—CH═CH, phenyl, phenyloxy, benzyl, benzyloxy, benzoyl,benzyloxybenzyl, or acyl radical, and where each R³ and R⁴ isindependently hydroxyl or an acyl radical. These include the compounds:3′-O-benzoyl-2,2′-anhydrouridine;3′-O-benzoyl-2,2′-anhydro-5-fluorouridine;3′-O-benzoyl-2,2′-anhydro-5-trifluoromethyluridine;3′-O-benzoyl-2,2′-anhydro-5-methyluridine;3′-O-benzoyl-2,2′-anhydro-5-ethyluridine;3′-O-benzoyl-2,2′-anhydro-5-propyluridine;3′-O-benzoyl-2,2′-anhydro-5-isopropyluridine;3′-O-benzoyl-2,2′-O-anhydro-5-isobutyluridine;3′-O-benzoyl-2,2′-anhydro-5-methylacyluridine;3′-O-benzoyl-2,2′-anhydro-5-propylacyluridine;3′-O-benzoyl-2,2′-anhydro-5-(2-bromovinyl)-uridine;3′-O-benzoyl-2,2′-anhydro-5-phenylluridine;3′-O-benzoyl-2,2′-anhydro-5-benzyluridine;3′-O-benzoyl-2,2′-anhydro-5-benzyoluridine; and3′-O-benzoyl-2,2′-anhydro-5-(benzyloxybenzyl)uridine;5′-O-benzoyl-2,2′-anhydrouridine;5′-O-benzoyl-2,2′-anhydro-5-fluorouridine;5′-O-benzoyl-2,2′-anhydro-5-trifluoromethyluridine;5′-O-benzoyl-2,2′-anhydro-5-methyluridine;5′-O-benzoyl-2,2′-anhydro-5-ethyluridine;5′-O-benzoyl-2,2′-anhydro-5-propyluridine;5′-O-benzoyl-2,2′-anhydro-5-isopropyluridine;5′-O-benzoyl-2,2′-O-anhydro-5-isobutyluridine;5′-O-benzoyl-2,2′-anhydro-5-methylacyluridine;5′-O-benzoyl-2,2′-anhydro-5-propylacyluridine;5′-O-benzoyl-2,2′-anhydro-5-(2-bromovinyl)-uridine;5′-O-benzoyl-2,2′-anhydro-5-phenylluridine;5′-O-benzoyl-2,2′-anhydro-5-benzyluridine;5′-O-benzoyl-2,2′-anhydro-5-benzyoluridine; and5′-O-benzoyl-2,2′-anhydro-5-(benzyloxybenzyl)uridine;3′,5′-O-benzoyl-2,2′-anhydrouridine;3′,5′-O-benzoyl-2,2′-anhydro-5-fluorouridine;3′5′-O-benzoyl-2,2′-anhydro-5-trifluoromethyluridine;3′,5′-O-benzoyl-2,2′-anhydro-5-methyluridine;3′,5′-O-benzoyl-2,2′-anhydro-5-ethyluridine;3′,5′-O-benzoyl-2,2′-anhydro-5-propyluridine;3′,5′-O-benzoyl-2,2′-anhydro-5-isopropyluridine;3′,5′-O-benzoyl-2,2′-O-anhydro-5-isobutyluridine;3′,5′-O-benzoyl-2,2′-anhydro-5-methylacyluridine;3′,5′-O-benzoyl-2,2′-anhydro-5-propylacyluridine;3′5′-O-benzoyl-2,2′-anhydro-5-(2-bromovinyl)-uridine;3′,5′-O-benzoyl-2,2′-anhydro-5-phenylluridine;3′,5′-O-benzoyl-2,2′-anhydro-5-benzyluridine;3′5′-O-benzoyl-2,2′-anhydro-5-benzyoluridine; and3′,5′-O-benzoyl-2,2′-anhydro-5-(benzyloxybenzyl)-uridine; or thepharmaceutically acceptable salts, solvates, hydrates, and prodrug formsthereof, and stereoisomers thereof.

Of specific interest is 3′-O-benzoyl-2,2′-anhydro-5-methyluridine,5′-O-benzoyl-2,2′-anhydro-5-methyluridine, and3′,5′-O-benzoyl-2,2′-anhydro-5-methyluridine, or the pharmaceuticallyacceptable salts, solvates, hydrates, and prodrug forms thereof, andstereoisomers thereof. Of specific interest are the β-D-arabinofuranosylisomers of these compounds, or the pharmaceutically acceptable salts,solvates, hydrates, and prodrug forms thereof.

In another embodiment, compounds according to formula (I) of specificinterest are those where R¹ and R⁴ are as defined above, and R² and/orR³ is a cyclic hydrocarbyl. By “cyclic hydrocarbyl” is intended ahydrocarbon-based ring structure having from 3 to about 10 carbon atoms,and having a single cyclic ring or multiple condensed rings that may besubstituted. Cyclic hydrocarbyls of interest are selected from aryl,aralkyl, aryloxy, aroyl, aroyloxy, heteroaryl, heteroaryloxy,heteroaroyloxy, cylcoalkyl, cycloalkyloxy and cycloalkoyloxy. Thus,cyclic hydrocarbyls of special interest are O-linked to the ribose orpyrimidine ring of formula (I). Compounds where R² and/or R³ is a cyclichydrocarbyl exhibit improved activity on a molar basis, or improvedspecificity with respect to not interfering with MTX efficacy.

Accordingly, certain compounds of the invention comprise a 5′-O-(cyclichydrocarbyl)-2,2′-anhydropyrimidine or derivative thereof. Thisembodiment includes 5′-O-(cyclic hydrocarbyl)-2,2′-anhydro-5(R⁵)-uridineor derivatives thereof, where R⁵ is R¹ (e.g., R⁵=R¹ where “5(R⁵)” refersto, and is the same as R¹ of formula (I)).

A compound of interest is 5′-O-aryl-2,2′-anhydropyrimidine or derivativethereof, of which various 2,2′-anhydrouridine derivatives are ofincluded. This includes compounds where the5′-O-aryl-2,2′-anhydropyrimidine is a 5′-O-aroyl-2,2′-anhydropyrimidine,such as: 5′-O-benzoyl-2,2′-anhydropyrimidine;5′-O-chlorobenzyl-2,2′-anhydropyrimidine;5′-O-nitrobenzyl-2,2′-anhydropyrimidine;5′-O-hydroxybenzyl-2,2′-anhydropyrimidine, and the like.

In one embodiment, compounds that exhibit improved activity on a molarbasis or improved specificity with respect to not interfering with MTXefficacy are the 5′-O-aryl-2,2′-anhydrouridines,5′-O-aroyl-2,2′-anhydrouridines, and derivatives thereof, such as5′-O-aryl-2,2′-anhydro-5(R⁴)-uridine,5′-O-aroyl-2,2′-anhydro-5(R⁴)-uridine, and their derivatives. Examplesinclude 5′-O-aryl-2,2′-anhydro-5-methyl-uridine;5′-O-aryl-2,2′-anhydro-5-ethyl-uridine;5′-O-aryl-2,2′-anhydro-5-propyl-uridine;5′-O-aryl-2,2′-anhydro-5-benzyl-uridine; and5′-O-aryl-2,2′-anhydro-5-(2-bromovinyl)-uridine; and derivativesthereof. Examples also include 5′-O-aroyl-2,2′-anhydro-5-methyl-uridine;5′-O-aroyl-2,2′-anhydro-5-ethyl-uridine;5′-O-aroyl-2,2′-anhydro-5-propyl-uridine;5′-O-aroyl-2,2′-anhydro-5-benzyl-uridine; and5-O-aroyl-2,2′-anhydro-5-(2-bromovinyl)-uridine; and derivativesthereof. Compounds of specific interest include5′-O-benzoyl-2,2′-anhydro-5(R⁴)-uridines, such as5′-O-benzoyl-2,2′-anhydro-5-methyl-uridine;5′-O-benzoyl-2,2′-anhydro-5-ethyl-uridine;5′-O-benzoyl-2,2′-anhydro-5-propyl-uridine;5′-O-benzoyl-2,2′-anhydro-5-benzyl-uridine; and5′-O-benzoyl-2,2′-anhydro-5-(2-bromovinyl)-uridine.

Stereoisomers of interest include the 5′-O-(cyclichydrocarbyl)-2,2′-anhydropyrimidines which are the β-D-isomers. Examplesinclude, but are not limited to:5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)uracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-fluorouracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-trifluoromethyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-ethyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-n-propyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-isopropyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-isobutyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyacyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-propylacyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-(2-bromovinyl)uracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-phenyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-benzyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-benzyoluracil; and5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-(3-benzyoxybenzyl)uracil.

As noted above, also of interest are analogues/derivatives of the abovecompounds, where such analogs/derivatives reduce MTX toxicity, such thatMTX toxicity is reduced when the compounds are administered inconjunction with MTX according to the subject invention. As alsoindicated above, an effective amount of MTX toxicity-reducing adjuvantis employed in the subject methods.

In certain embodiments, the amount of MTX toxicity-reducing adjuvantemployed is more than the amount of the MTX active agent employed. Incertain embodiments, the amount of MTX toxicity-reducing adjuvant is anamount that is less than equimolar to the amount of MTX active agentthat is administered. Typically, the amount of toxicity-reducingadjuvant that is administered is less than about 75%, less than about50%, less then about 25% and many embodiments less than about 15%, lessthan about 10% and even less than about 5% or 1% than the amount of MTXactive agent. In one embodiment, the effective amount is about 1% to 50%of the amount of the MTX active agent, such as about 3% to 40%, andincluding about 5% to 30% of the amount of the MTX active agent. Inother embodiments, the effective amount is the same as the amount of theactive agent, and in certain embodiments the effective amount is anamount that is more than the amount of the MTX active agent. Effectiveamounts can readily be determined empirically using the data provided inthe Experimental section below.

The 2,2′-anhydropyrimidine and derivatives thereof described above arecommercially available or can be conventionally prepared by techniquesknown to one of skill in the art. For example, representative patentsdescribing various 2,2′-anhydropyrimidine and derivatives, includingintermediates and precursors, analysis, as well as thesynthesis/preparation thereof, include U.S. Pat. Nos. 3,975,367;4,145,531; 4,230,698; 4,247,544; 4,544,740; 4,604,382; 4,613,604;4,681,933; 4,841,039; 4,916,122; 4,987,224; 5,008,384; 5,077,280;5,084,445; 5,141,943; 5,190,926; 5,212,293; 5,278,167; 5,384,396;5,455,339; 5,476,855; 5,596,093; 5,610,292; 5,721,241; 5,723,449;5,739,314; 5,760,202; 5,889,013; 5,861,493; 6,060,592; 6,090,932;6,222,025; 6,369,040; 6,642,367; 6,670,461; 6,867,290; and 7,176,295;the disclosures of which are herein incorporated by reference. See also,the following references: Veres et al., Biochem Pharmacol. 34(10):1737(1985); Veres et al., Drugs Exp Clin Res. 13(10):615 (1987); el Konui etal, Mol. Pharmacology. 34:104 (1988); Cienfuegos et al. Org. Lett.7(11):2161 (2005); Choi et al., Nucleosides Nucleotides Nucleic Acids22(5-8):547 (2003); Rodriquez et al., J Med Chem 37(20):3389 (1994);McGee, D. P. C. et al., “Novel Nucleosides via IntramolecularFunctionalization of 2,2′ Anahydrouridine Derivatives”, Tetr. Lett.,37(12):1995 (1996); Machulla et al. J. Nucl. Med. 42(5):257 (2001);Czernecki S. et al. Nucleosides & Nucleotides 14:1227 (1995);Heterocyclic Chemistry (3rd Edition), Thomas. L. Gilchrist, PrenticeHall (1997); Movassaghi, M. and M. D. Hill, J. Am. Chem. Soc.128(44):14254 (2006); Brown, D. J. Heterocyclic Compounds: ThePyrimidines. Vol 52. New York: Interscience, 1994; Eaton, (1995) Annu.Rev. Biochem. 64, 837; Usman and Cedergreen TIBS 17:334 (1992); Greeneand Wuts (1991) Protective Groups in Organic Synthesis, 2nd Ed, WileyInterscience); Moffatt, (1979) Nucleoside Analogues, Ed. Walker, N Y,Plenum.; Townsend, (1988) Chemistry of Nucleosides and Nucleotides, N Y,Plenum; and Sproat, et al., (1991) Oligonucleotides and Analogues: APractical Approach, ed. F. Eckstein, NY. Oxford Univ. Press)).

Of particular interest are 2,2′-anhydropyrimidines and derivativesthereof that are inhibitors of uridine phosphorylase. Uridinephosphorylase (UPh; EC 2.4.2.3) is a member of the pyrimidine nucleosidephosphorylase family of enzymes which catalyzes the phosphorolyticcleavage of the C—N glycoside bond of uridine, with the formation ofribose 1-phosphate and uracil (Timofeev et al., Acta Crystallogr Sect FStruct Biol Cryst Commun., 63: 852-854 (2007)).

The scope of the present invention includes prodrugs of the MTX activeagent and the MTX toxicity-reducing adjuvant. Such prodrugs are, ingeneral, functional derivatives of the compounds that are readilyconvertible in vivo into the required compounds. Thus, in the methods ofthe present invention, the term “administering” encompassesadministering the compound specifically disclosed or with a compoundwhich may not be specifically disclosed, but which converts to thespecified compound in vivo after administration to the subject in needthereof. Conventional procedures for the selection and preparation ofsuitable prodrug derivatives are described, e.g., in Wermuth, “DesigningProdrugs and Bioprecursors” in Wermuth, ed. The Practice of MedicinalChemistry, 2d Ed., pp. 561-586 (Academic Press 2003). Prodrugs includeesters that hydrolyze in vivo (e.g., in the human body) to produce acompound described herein suitable for the present invention. Suitableester groups include, without limitation, those derived frompharmaceutically acceptable, aliphatic carboxylic acids, particularlyalkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which eachalkyl or alkenyl moiety has no more than 6 carbon atoms. Illustrativeesters include formates, acetates, propionates, butyrates, acrylates,citrates, succinates, and ethylsuccinates.

Formulations

Also provided are pharmaceutical compositions containing the MTX activeagent and/or the MTX toxicity-reducing adjuvant employed in the subjectmethods. Accordingly, the MTX active agent and/or the MTXtoxicity-reducing adjuvant in pharmaceutical compositions, e.g., in theform of a pharmaceutically acceptable salt, can be formulated for oral,topical or parenteral administration for use in the subject methods, asdescribed above. In certain embodiments, e.g., where the compounds areadministered as separate formulations (such as in those embodimentswhere they are administered sequentially), separate or distinctpharmaceutical compositions, each containing a different active agent,are provided. In yet other embodiments, a single formulation thatincludes both of the MTX active agent and the MTX toxicity-reducingadjuvant (i.e., one composition that includes both active agents) isprovided.

By way of illustration, the MTX active agent and/or the MTXtoxicity-reducing adjuvant can be admixed with conventionalpharmaceutically acceptable carriers and excipients (i.e., vehicles) andused in the form of aqueous solutions, tablets, capsules, elixirs,suspensions, syrups, wafers, and the like. Such pharmaceuticalcompositions contain, in certain embodiments, from about 0.1% to about90% by weight of the active compound, and more generally from about 1%to about 30% by weight of the active compound. The pharmaceuticalcompositions may contain common carriers and excipients, such as cornstarch or gelatin, lactose, dextrose, sucrose, microcrystallinecellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, andalginic acid. Disintegrators commonly used in the formulations of thisinvention include croscarmellose, microcrystalline cellulose, cornstarch, sodium starch glycolate and alginic acid.

A liquid composition will generally consist of a suspension or solutionof the compound or pharmaceutically acceptable salt in a suitable liquidcarrier(s), for example, ethanol, glycerine, sorbitol, non-aqueoussolvent such as polyethylene glycol, oils or water, with a suspendingagent, preservative, surfactant, wetting agent, flavoring or coloringagent. Alternatively, a liquid formulation can be prepared from areconstitutable powder.

For example, a powder containing active compound, suspending agent,sucrose and a sweetener can be reconstituted with water to form asuspension; and a syrup can be prepared from a powder containing activeingredient, sucrose and a sweetener.

A composition in the form of a tablet can be prepared using any suitablepharmaceutical carrier(s) routinely used for preparing solidcompositions. Examples of such carriers include magnesium stearate,starch, lactose, sucrose, microcrystalline cellulose and binders, forexample, polyvinylpyrrolidone. The tablet can also be provided with acolor film coating, or color included as part of the carrier(s). Inaddition, active compound can be formulated in a controlled releasedosage form as a tablet comprising a hydrophilic or hydrophobic matrix.

A composition in the form of a capsule can be prepared using routineencapsulation procedures, for example, by incorporation of activecompound and excipients into a hard gelatin capsule. Alternatively, asemi-solid matrix of active compound and high molecular weightpolyethylene glycol can be prepared and filled into a hard gelatincapsule; or a solution of active compound in polyethylene glycol or asuspension in edible oil, for example, liquid paraffin or fractionatedcoconut oil can be prepared and filled into a soft gelatin capsule.

Tablet binders that can be included are acacia, methylcellulose, sodiumcarboxymethylcellulose, poly-vinylpyrrolidone (Povidone), hydroxypropylmethylcellulose, sucrose, starch and ethylcellulose. Lubricants that canbe used include magnesium stearate or other metallic stearates, stearicacid, silicone fluid, talc, waxes, oils and colloidal silica.

Flavoring agents such as peppermint, oil of wintergreen, cherryflavoring or the like can also be used. Additionally, it may bedesirable to add a coloring agent to make the dosage form moreattractive in appearance or to help identify the product.

The compounds of the invention and their pharmaceutically acceptablesalts that are active when given parenterally can be formulated forintramuscular, intrathecal, or intravenous administration.

A typical composition for intramuscular or intrathecal administrationwill be of a suspension or solution of active ingredient in an oil, forexample, arachis oil or sesame oil. A typical composition forintravenous or intrathecal administration will be a sterile isotonicaqueous solution containing, for example, active ingredient and dextroseor sodium chloride, or a mixture of dextrose and sodium chloride. Otherexamples are lactated Ringer's injection, lactated Ringer's plusdextrose injection, Normosol-M and dextrose, Isolyte E, acylatedRinger's injection, and the like. Optionally, a co-solvent, for example,polyethylene glycol, a chelating agent, for example, ethylenediaminetetracetic acid, and an anti-oxidant, for example, sodium metabisulphitemay be included in the formulation. Alternatively, the solution can befreeze dried and then reconstituted with a suitable solvent just priorto administration.

The compounds of the invention and their pharmaceutically acceptablesalts which are active on rectal administration can be formulated assuppositories. A typical suppository formulation will generally consistof active ingredient with a binding and/or lubricating agent such as agelatin or cocoa butter or other low melting vegetable or synthetic waxor fat.

The compounds of this invention and their pharmaceutically acceptablesalts which are active on topical administration can be formulated astransdermal compositions or transdermal delivery devices (“patches”).Such compositions include, for example, a backing, active compoundreservoir, a control membrane, liner and contact adhesive. Suchtransdermal patches may be used to provide continuous or discontinuousinfusion of the compounds of the present invention in controlledamounts. The construction and use of transdermal patches for thedelivery of pharmaceutical agents is well known in the art. See, e.g.,U.S. Pat. No. 5,023,252, herein incorporated by reference in itsentirety. Such patches may be constructed for continuous, pulsatile, oron demand delivery of pharmaceutical agents.

In certain embodiments of interest, the MTX active agent and the MTXtoxicity-reducing adjuvant are administered as a single pharmaceuticalformulation, that, in addition to including an effective amount of theactive agent and the toxicity-reducing adjuvant, includes other suitablecompounds and carriers, and may also be used in combination with otheractive agents. The present invention, therefore, also includespharmaceutical compositions comprising pharmaceutically acceptableexcipients. The pharmaceutically acceptable excipients include, forexample, any suitable vehicles, adjuvants, carriers or diluents, and arereadily available to the public. The pharmaceutical compositions of thepresent invention may further contain other active agents that are wellknown in the art.

One skilled in the art will appreciate that a variety of suitablemethods of administering a formulation of the present invention to asubject or host, e.g., patient, in need thereof, are available, and,although more than one route can be used to administer a particularformulation, a particular route can provide a more immediate and moreeffective reaction than another route. Pharmaceutically acceptableexcipients are also well-known to those who are skilled in the art andare readily available. The choice of excipient will be determined inpart by the particular compound, as well as by the particular methodused to administer the composition. Accordingly, there are a widevariety of suitable formulations of the pharmaceutical composition ofthe present invention. The following methods and excipients are merelyexemplary and are in no way limiting.

Formulations suitable for oral administration can consist of (a) liquidsolutions, such as an effective amount of the compound dissolved indiluents, such as water, saline, or orange juice; (b) capsules, sachetsor tablets, each containing a predetermined amount of the activeingredient, as solids or granules; (c) suspensions in an appropriateliquid; and (d) suitable emulsions. Tablet forms can include one or moreof lactose, mannitol, corn starch, potato starch, microcrystallinecellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellosesodium, talc, magnesium stearate, stearic acid, and other excipients,colorants, diluents, buffering agents, moistening agents, preservatives,flavoring agents, and pharmacologically compatible excipients. Lozengeforms can comprise the active ingredient in a flavor, usually sucroseand acacia or tragacanth, as well as pastilles comprising the activeingredient in an inert base, such as gelatin and glycerin, or sucroseand acacia, emulsions, gels, and the like containing, in addition to theactive ingredient, such excipients as are known in the art.

The subject formulations of the present invention can be made intoaerosol formulations to be administered via inhalation. These aerosolformulations can be placed into pressurized acceptable propellants, suchas dichlorodifluoromethane, propane, nitrogen, and the like. They mayalso be formulated as pharmaceuticals for non-pressured preparationssuch as for use in a nebulizer or an atomizer.

Formulations suitable for parenteral administration include aqueous andnon-aqueous, isotonic sterile injection solutions, which can containanti-oxidants, buffers, bacteriostats, and solutes that render theformulation isotonic with the blood of the intended recipient, andaqueous and non-aqueous sterile suspensions that can include suspendingagents, solubilizers, thickening agents, stabilizers and preservatives.The formulations can be presented in unit-dose or multi-dose sealedcontainers, such as ampules and vials, and can be stored in afreeze-dried (lyophilized) condition requiring only the addition of thesterile liquid excipient, for example, water, for injections,immediately prior to use. Extemporaneous injection solutions andsuspensions can be prepared from sterile powders, granules, and tabletsof the kind previously described.

Formulations suitable for topical administration may be presented ascreams, gels, pastes, or foams, containing, in addition to the activeingredient, and other such carriers that are known in the art to beappropriate.

Suppository formulations are also provided by mixing with a variety ofbases such as emulsifying bases or water-soluble bases. Formulationssuitable for vaginal administration may be presented as pessaries,tampons, creams, gels, pastes, foams.

Unit dosage forms for oral or rectal administration such as syrups,elixirs, and suspensions may be provided wherein each dosage unit, forexample, teaspoonful, tablespoonful, tablet or suppository, contains apredetermined amount of the composition containing one or moreinhibitors. Similarly, unit dosage forms for injection or intravenousadministration may comprise the inhibitor(s) in a composition as asolution in sterile water, normal saline or another pharmaceuticallyacceptable carrier.

The term “unit dosage form,” as used herein, refers to physicallydiscrete units suitable as unitary dosages for human and animalsubjects, each unit containing a predetermined quantity of compounds ofthe present invention calculated in an amount sufficient to produce thedesired effect in association with a pharmaceutically acceptablediluent, carrier or vehicle. The specifications for the novel unitdosage forms of the present invention depend on the particular compoundemployed and the effect to be achieved, and the pharmacodynamicsassociated with each compound in the host.

Those of skill in the art will readily appreciate that dose levels canvary as a function of the specific compound, the nature of the deliveryvehicle, and the like. Suitable dosages for a given compound are readilydeterminable by those of skill in the art by a variety of means.

The dose administered to an animal, particularly a human, in the contextof the present invention should be sufficient to cause a prophylactic ortherapeutic response in the animal over a reasonable time frame. Oneskilled in the art will recognize that dosage will depend on a varietyof factors including the strength of the particular compound employed,the condition of the animal, and the body weight of the animal, as wellas the severity of the illness and the stage of the disease. The size ofthe dose will also be determined by the existence, nature, and extent ofany adverse side-effects that might accompany the administration of aparticular compound. Suitable doses and dosage regimens can bedetermined by comparisons to anticancer or immunosuppressive agents thatare known to cause the desired growth inhibitory or immunosuppressiveresponse.

Optionally, the pharmaceutical composition may contain otherpharmaceutically acceptable components, such a buffers, surfactants,antioxidants, viscosity modifying agents, preservatives and the like.Each of these components is well-known in the art. For example, see U.S.Pat. No. 5,985,310, the disclosure of which is herein incorporated byreference.

Other components suitable for use in the formulations of the presentinvention can be found in Remington's Pharmaceutical Sciences, MacePublishing Company, Philadelphia, Pa., 17th ed. (1985). In anembodiment, the aqueous solution of cyclodextrin also contains dextrose,e.g., about 5% dextrose.

Utility

The subject methods find use in a variety of applications. In certainapplications, the methods are methods of modulating at least onecellular function, such as DHFR mediation of DNA synthesis and/orrepair. In this respect, the subject methods and compositions find usein known applications of MTX, such as in treating diseases or disordersthat are capable of being treated using MTX. Use of the subjectcompositions of the present invention is of particular utility in, forexample, the treatment of diseases and disorders including, but notlimited to, cancer, psoriasis, rheumatoid arthritis, Crohn's disease andtissue-graft rejection, as well as in conditions requiringimmunosuppressive agents. In these capacities, use of the presentinventive compositions will result in reduced toxicity while retainingthe desired MTX activity.

As such, the subject methods and compositions find use in therapeuticapplications in which MTX administration is indicated. A representativetherapeutic application is in the treatment of cellular proliferativedisease conditions, e.g., cancers and related conditions characterizedby abnormal cellular proliferation. Such disease conditions includecancer and neoplastic diseases and other diseases characterized by thepresence of unwanted cellular proliferation, e.g., hyperplasias, and thelike. Autoimmune diseases like multiple sclerosis also featureinappropriate proliferation of immune cells.

By treatment, is meant that at least an amelioration of the symptomsassociated with the condition afflicting the host is achieved, whereamelioration is used in a broad sense to refer to at least a reductionin the magnitude of a parameter, e.g. a symptom associated with thecondition being treated or an side effect resulting from administrationof a drug. As such, treatment also includes situations where thepathological condition, or at least symptoms associated therewith, arecompletely inhibited, e.g., prevented from happening, or stopped, e.g.terminated, such that the host no longer suffers from the condition, orat least the symptoms that characterize the condition.

A specific application of interest is the use of anhydronucleosides,particularly 2,2′-anhydropyrimidines and derivatives thereof, toameliorate MTX-induced mucositis. Thus, in certain embodiments, a methodis provided for the treatment of a host in need thereof an effectiveamount of a MTX active agent in conjunction with an amount of an MTXtoxicity-reducing adjuvant effective to reduce MTX-induced mucositis inthe host, wherein the MTX toxicity-reducing adjuvant is a2,2′-anhydropyrimidine or derivative thereof. In a related embodiment,the MTX-induced mucositis is stomatitis. In another related embodiment,the MTX-induced mucositis is characterized by one or more featuresselected from myelosuppression, weight loss, inflammation, andinfection. Of specific interest is the use of2,2′-anhydro-5-methyluridine and acyl derivatives thereof as the MTXtoxicity-reducing adjuvant to reduce MTX-induced mucositis in the host.

Reduction of MTX-induced mucositis is characterized by the prevention,mitigation, or reduction of the likelihood of onset of mucositisresulting from treatment of a host with an MTX active agent. Thisincludes treatment of a host in need thereof with an effective amount ofa MTX active agent in conjunction with an amount of an MTXtoxicity-reducing adjuvant effective to reduce MTX-induced mucositis inthe host, where the MTX toxicity-reducing adjuvant improves thelikelihood of successfully preventing or eliminating one or morefeatures of mucositis when it has occurred including: (i) prevention,that is, causing the clinical symptoms not to develop, e.g., preventingmyelosuppression, weight loss, inflammation, and/or infection, and/orpreventing progression of one or more of these features to a harmfulstate; (ii) inhibition, that is, arresting the development or furtherdevelopment of clinical symptoms, e.g., mitigating or completelyinhibiting an active (ongoing) feature of mucositis so that the featureis decreased to the degree that it is no longer seriously harmful, whichdecrease can include complete elimination of mucositis from the host;and/or (iii) relief, that is, causing the regression of clinicalsymptoms, e.g., causing a relief of myelosuppression, weight loss,inflammation, infection, and/or other symptoms caused by treatment ofthe host with an MTX active agent.

For example, mucositis severity, including oral mucositis (stomatitis),can easily be assessed by visual inspection of mouth, throat and/or anallesions associated with the condition, interrogation of test subjects orpatients (do you have soreness of the mouth or throat?) or by use ofany, or all, three well accepted disease scales: the five-grade WorldHealth Organization (WHO) oral-toxicity scale (Miller A B et al., Cancer1981; 47:207-214), the five-grade Radiation Therapy Oncology Group(RTOG) acute radiation-morbidity scoring criteria for mucous membranes,National Cancer Institute common toxicity criteria, version 2.0. Apr.30, 1999 and the four-grade Western Consortium for Cancer NursingResearch (WCCNR) revised staging system for oral mucositis. Assessingstomatitis: refinement of the Western Consortium for Cancer NursingResearch (WCCNR) stomatitis staging system (Can Oncol Nurs J 1998;8:160-165). Thus, the effect of treatment with a MTX toxicity reducingadjuvant can readily be determined using any, or all, of these testsystems.

A variety of subjects are treatable according to the subject methods.Generally such hosts are “mammals” or “mammalian,” where these terms areused broadly to describe organisms which are within the class mammalia,including the orders carnivore (e.g., dogs and cats), rodentia (e.g.,mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees,and monkeys). In many embodiments, the subjects will be humans.

In certain embodiments, the subjects will be subjects that have beendiagnosed for and are, therefore, in need of administration of theactive agent. In certain embodiments, the methods may include diagnosingthe subject for the presence of the disease condition to be treated byadministration of the active agent.

The subject methods find use in, among other applications, the treatmentof cellular proliferative disease conditions, including neoplasticdisease conditions, e.g., cancers, and autoimmune diseases. In suchapplications, an effective amount of the MTX active agent and MTXtoxicity-reducing adjuvant is administered to the subject in needthereof. Treatment is used broadly as defined above, to include at leastamelioration in one or more of the symptoms of the disease, as well as acomplete cessation thereof, as well as a reversal and/or completeremoval of the disease condition, i.e., a cure.

There are many disorders associated with a dysregulation of cellularproliferation, e.g., cellular proliferative disorders. The conditions ofinterest include, but are not limited to, conditions described below.

The subject methods may be employed in the treatment of a variety ofconditions where there is proliferation and/or migration of smoothmuscle cells, and/or inflammatory cells into the intimal layer of avessel, resulting in restricted blood flow through that vessel, e.g.neointimal occlusive lesions. Occlusive vascular conditions of interestinclude atherosclerosis, graft coronary vascular disease aftertransplantation, vein graft stenosis, peri-anastomatic prosthetic graftstenosis, restenosis after angioplasty or stent placement, and the like.

Diseases where there is hyperproliferation and tissue re-modeling orrepair of reproductive tissue, e.g. uterine, testicular and ovariancarcinomas, endometriosis, squamous and glandular epithelial carcinomasof the cervix, etc. are reduced in cell number by administration of thesubject compounds

Tumors of interest for treatment include carcinomas, e.g. colon,duodenal, prostate, breast, melanoma, ductal, hepatic, pancreatic,renal, endometrial, stomach, dysplastic oral mucosa, polyposis, invasiveoral cancer, non-small cell lung carcinoma, transitional and squamouscell urinary carcinoma etc.; neurological malignancies, e.g.neuroblastoma, gliomas, etc.; hematological malignancies, e.g. childhoodacute leukemia, acute myelogenous leukemias, acute lymphocytic leukemia,non-Hodgkin's lymphomas, chronic lymphocytic leukaemia, malignantcutaneous T-cells, mycosis fungoides, non-MF cutaneous T-cell lymphoma,lymphomatoid papulosis, T-cell rich cutaneous lymphoid hyperplasia,bullous pemphigoid, discoid lupus erythematosus, lichen planus,gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole,epidermoid cancers of the head and neck, trophoblastic neoplasms such aschoriocarcinoma, chorioadenoma destruens, hydatidiform mole, etc., andthe like.

Some cancers of particular interest include breast cancers, which areprimarily adenocarcinoma subtypes. Ductal carcinoma in situ (DCIS) isthe most common type of noninvasive breast cancer. In DCIS, themalignant cells have not metastasized through the walls of the ductsinto the fatty tissue of the breast. Infiltrating (or invasive) ductalcarcinoma (IDC) has metastasized through the wall of the duct andinvaded the fatty tissue of the breast. Infiltrating (or invasive)lobular carcinoma (ILC) is similar to IDC, in that it has the potentialmetastasize elsewhere in the body. About 10% to 15% of invasive breastcancers are invasive lobular carcinomas.

Also of interest is non-small cell lung carcinoma. Non-small cell lungcancer (NSCLC) is made up of three general subtypes of lung cancer.Epidermoid carcinoma (also called squamous cell carcinoma) usuallystarts in one of the larger bronchial tubes and grows relatively slowly.The size of these tumors can range from very small to quite large.Adenocarcinoma starts growing near the outside surface of the lung andmay vary in both size and growth rate. Some slowly growingadenocarcinomas are described as alveolar cell cancer. Large cellcarcinoma starts near the surface of the lung, grows rapidly, and thegrowth is usually fairly large when diagnosed. Other less common formsof lung cancer are carcinoid, cylindroma, mucoepidermoid, and malignantmesothelioma.

Melanoma is a malignant tumor of melanocytes. Although most melanomasarise in the skin, they also may arise from mucosal surfaces or at othersites to which neural crest cells migrate. Melanoma occurs predominantlyin adults, and more than half of the cases arise in apparently normalareas of the skin. Prognosis is affected by clinical and histologicalfactors and by anatomic location of the lesion. Thickness and/or levelof invasion of the melanoma, mitotic index, tumor infiltratinglymphocytes, and ulceration or bleeding at the primary site affect theprognosis. Clinical staging is based on whether the tumor has spread toregional lymph nodes or distant sites. For disease clinically confinedto the primary site, the higher the chance of lymph node metastases andthe worse the prognosis is associated with greater thickness and depthof the local invasion of the melanoma. Melanoma can spread by localextension (through lymphatics) and/or by hematogenous routes to distantsites. Any organ may be involved by metastases, but lungs and liver arecommon sites.

Other proliferative diseases of interest relate to epidermalhyperproliferation, tissue remodelling and repair. For example, thechronic skin inflammation of psoriasis is associated with hyperplasticepidermal keratinocytes as well as infiltrating mononuclear cells,including CD4+ memory T cells, neutrophils and macrophages.

The methods of the present invention can provide a method of treatingmany, if not most, malignancies, including tumors derived from cellsselected from skin, connective tissue, adipose, breast, lung, stomach,pancreas, ovary, cervix, uterus, kidney, bladder, colon, prostate,central nervous system (CNS), retina and blood, and the like.Representative cancers of interest include, but are not limited to,head, neck and lung tissue (e.g., head and neck squamous cell carcinoma,non-small cell lung carcinoma, small cell lung carcinoma)gastrointestinal tract and pancreas (e.g., gastric carcinoma, colorectaladenoma, colorectal carcinoma, pancreatic carcinoma); hepatic tissue(e.g., hepatocellular carcinoma), kidney and urinary tract (e.g.,dysplastic urothelium, bladder carcinoma, renal carcinoma, Wilms tumor),breast (e.g., breast carcinoma); neural tissue (e.g., retinoblastoma,oligodendroglioma, neuroblastoma, and malignant meningioma; skin (e.g.,normal epidermis, squamous cell carcinoma, basal cell carcinoma,melanoma, etc.).

The methods of the present invention also can provide a method oftreating hematological tissues (e.g., lymphoma, chronic myeloid leukemia(CML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia(ALL), acute myeloid leukemia (AML), etc., and the like.

The dose administered to an animal, particularly a human, in the contextof the present invention should be sufficient to affect a prophylacticor therapeutic response in the animal over a reasonable time frame. Oneskilled in the art will recognize that dosage will depend on a varietyof factors including the strength of the particular compound employed,the dose of methotrexate, the dosing regimen used for methotrexate, thecondition of the animal, and the body weight of the animal, as well asthe severity of the illness and the stage of the disease.

The size of the dose will also be determined by the existence, nature,and extent of any adverse side-effects that might accompany theadministration of a particular compound.

In the treatment of some individuals with the compounds of the presentinvention, it may be desirable to use a high dose regimen in conjunctionwith a rescue agent for non-malignant cells. In such treatment, anyagent capable of rescue of non-malignant cells can also be employed,such as citrovorum factor, folate derivatives, or Leucovorin in additionto the adjuvant. Such rescue agents are well known to those of ordinaryskill in the art.

Particular applications in which the subject methods and compositionsfind use include those described in U.S. Pat. Nos. 2,512,572; 3,892,801;3,989,703; 4,057,548; 4,067,867; 4,079,056; 4,080,325; 4,136,101;4,224,446; 4,306,064; 4,374,987; 4,421,913; 4,767,859; 3,981,983;4,043,759; 4,093,607; 4,279,992; 4,376,767; 4,401,592; 4,489,065;4,622,218; 4,625,014; 4,638,045; 4,671,958; 4,699,784; 4,785,080;4,816,395; 4,886,780; 4,918,165; 4,925,662; 4,939,240; 4,983,586;4,997,913; 5,024,998; 5,028,697; 5,030,719; 5,057,313; 5,059,413;5,082,928; 5,106,950; 5,108,987; 4,106,488; 4,558,690; 4,662,359;4,396,601; 4,497,796; 5,043,270; 5,166,149; 5,292,731; 5,354,753;5,382,582; 5,698,556; 5,728,692; and 5,958,928; the disclosures of whichare herein incorporated by reference.

Kits & Systems

Also provided are kits and systems that find use in practicing thesubject methods, as described above. For example, kits and systems forpracticing the subject methods may include one or more pharmaceuticalformulations, which include one or both of the MTX active agent and MTXtoxicity-reducing adjuvant. As such, in certain embodiments the kits mayinclude a single pharmaceutical composition, present as one or more unitdosages, where the composition includes both the MTX active agent andMTX toxicity-reducing adjuvant. In yet other embodiments, the kits mayinclude two or more separate pharmaceutical compositions, eachcontaining either a MTX active agent or a MTX toxicity-reducingadjuvant.

In addition to the above components, the subject kits may furtherinclude instructions for practicing the subject methods. Theseinstructions may be present in the subject kits in a variety of forms,one or more of which may be present in the kit. One form in which theseinstructions may be present is as printed information on a suitablemedium or substrate, e.g., a piece or pieces of paper on which theinformation is printed, in the packaging of the kit, in a packageinsert, etc. Yet another means would be a computer readable medium,e.g., diskette, CD, etc., on which the information has been recorded.Yet another means that may be present is a website address which may beused via the internet to access the information at a removed site. Anyconvenient means may be present in the kits. For example, a kitaccording to one embodiment includes as a first component (a)instructions for using a MTX toxicity-reducing adjuvant, and as a secondcomponent (b) a pharmaceutical composition comprising a MTXtoxicity-reducing adjuvant, a MTX active agent, or a combinationthereof.

Kits of specific interest are those that include a2,2′-anhydropyrimidine pharmaceutical composition of the invention andsuitable for practicing the subject methods of the invention, such asfor reducing MTX active agent-induced mucositis, including stomatitis,and such as for treatment of a cellular proliferative disorder.

The term “system” as employed herein refers to a collection of a MTXactive agent and a MTX toxicity-reducing adjuvant, present in a singleor disparate composition, that are brought together for the purpose ofpracticing the subject methods. For example, separately obtained MTXactive agent and MTX toxicity-reducing adjuvant dosage forms broughttogether and co-administered to a subject, according to the presentinvention, are a system according to the present invention.

The following examples further illustrate the present invention butshould not be construed in any way as limiting its scope.

EXPERIMENTAL

I. Fly Study I (Protection from Lethality)

The efficacy of cancer chemotherapy can be improved if agents areavailable to reduce the adverse events associated with treatment withcytotoxic agents. To this end, Drosophila melanogaster (commonly know asthe fruit fly) is an ideal organism to screen chemical compounds forsuch side-effect-reducing agents. This study is aimed at finding a doseof a 2,2′-anhydropyrimidine test article that protects againstMTX-induced lethality in insects.

Increasing amounts of a 2,2′-anhydropyrimidine test article (typically0.03 to 0.1 mg) are mixed in an aqueous solution with 0.3 (or 0.4) mgMTX. Four milliliters (mL) of a 2,2′-anhydropyrimidine test article+MTXsolutions are added to an appropriate amount of instant fly medium.Fruit fly eggs are added to a 2,2′-anhydropyrimidine test article+MTXtreated medium and incubated for up to 31 days. After the 31 dayincubation, each assay is scored by the number of mature fly and pupaeper vial.

The assays are set up in clear sterile polystyrene narrow diameter vialsfrom Applied Scientific (Hampton, N.H.). Vials are stored in trays andincubated in a darkened 25° C. incubator.

Reagents and materials used are: 50 mg/mL MTX in H₂O (pH 8), 20 mg/mL ofthe 2,2′-anhydropyrimidine test article in H₂O, water, sterilepolystyrene narrow diameter vials from Applied Scientific, InstantDrosophila Food Medium, Oregon-R Drosophila melanogaster, 25° C.incubator, and 15 mL polystyrene conical tubes

Each assay is performed in a separate fly vial. Increasing amounts of a2,2′-anhydropyrimidine (0.005 to 1.0 mg) are tested for MTXside-effect-reduction on fly eggs. Amounts of the 2,2′-anhydropyrimidinetest article are drawn from a 20 mg/mL stock solution dissolved inwater. Nine mL of the 2,2′-anhydropyrimidine+0.3 (or 0.4) mg MTXsolutions are pre-mixed with water in a 15 mL conical tube. Duplicateassays receive 4 mL of the 2,2′-anhydropyrimidine test article+0.3 (or0.4) mg MTX solutions. Pre-measured amounts of instant drosophila mediumare added to each assay to achieve optimal hydration level. Controls are(1) 4 mL water alone and (2) 0.3 (or 0.4) mg MTX alone. Precisely 50 flyeggs aged for ˜18 hours are added to each assay. Assays are capped witha fitted plug and incubated for 30 days in a darkened 25° C. incubator.Assays are scored by the number of dead pupae or adult flies per vial.

A typical set of results of the toxicity curve for MTX in the fly modelis provided in FIG. 1, which depicts the protective effect of arepresentative 2,2′-anhydropyrimidine test article(2,2′-anhydro-5-methyluridine, also referred to as TK-112690) onlethality in the fly model. Group 6 corresponds to the saline treatedflies. Group 5 corresponds to the MTX treated flies. Groups 1-4correspond to the MTX+TK-112690 treated flies. Doses of MTX were 0.4 mgand doses of TK-112690 ranged from 0.005 to 0.1 mg.

The data illustrated in FIG. 1 show that the effect of MTX on lethalityin the flies was highly significant (p<0.01 for the difference betweenGroups 5 and 6), while the protection afforded by TK-112690 was highlysignificant (p<0.01 for the difference between Groups 1-4 and eitherGroups 5 or 6). These data demonstrate that 2,2′-anhydropyrimidines,such as TK-112690, reduce MTX toxicity.

II. Mouse Study I (Protection from Weight Loss)

The efficacy of cancer chemotherapy can be improved if agents areavailable to reduce the adverse events associated with treatment withcytotoxics. To this end, mice are an ideal organism to further analyzeprotecting agents originally identified in a fly model. The aim of thisstudy is to find a dose of a representative a 2,2′-anhydropyrimidinetest article that protects in a mouse against MTX-induced weight loss, acardinal feature of mucositis.

This mouse model is modified from a published procedure (de Koning etal., Int Immunol 18: 941 (2006)). Mice are treated on day one with asingle intraperitoneal (ip) dose of lipopolysaccharide (LPS), followedby two consecutive days with 200 and 100 mg/kg ip methotrexate,respectively. Controls include saline alone for days 1, 2, and 3, salineon day 1 plus MTX on days 2 and 3 and LPS on day one with salineinjection on days 2 and 3. Experimental groups are given LPS on day oneand 10 or 30 mg/kg, TK-112690, a representative 2,2′-anhydropyrimidinetest article, ip 3 hours before, and 3 hours after, methotrexateinjection on days 2 and 3. Animal weights are measured every day afterthe first injection with experiment termination five days after thesecond methotrexate injection (day 8). Weight loss is representative ofMTX-induced toxicity, and one aspect of MTX-induced mucositis.

Typical results for TK-112690 are presented in FIG. 2. In this plot,Group1 corresponds to the saline treated mice. Group 2 corresponds tothe lipopolysaccharide (LPS) treated mice. Group 3 corresponds to theMTX treated mice. Group 4 corresponds to the LPS+MTX treated mice. Group5 corresponds to the LPS+MTX+TK-112690 (10 mg/kg) treated mice. Group 6corresponds to mice treated with LPS+methotrexate+TK-112690 (30 mg/kg).The ordinate in the Figure is the mean of the weight difference betweenstudies Day 1 and 8.

The protection obtained with TK-112690 in this study was highlysignificant (Group 5 mean weight change versus Group 4 (p<0.004) andGroup 6 versus Group 4 (p<0.0005). The effect of the 30 mg/kg dose isgreater than the effect of the 10 mg/kg dose. Groups 5 and 6 are notstatistically different from Group 1 (saline).

These results demonstrate that treatment with a 2,2′-anhydropyrimidinetest article reduces MTX-induced toxicity in a mammalian host, and thatthe protective effect of 2,2′-anhydropyrimidine is dose dependent.

III. Mouse Study II (Protection from Loss of Mucosal Permeability)

The aim of this study was to evaluate the ability of a representative a2,2′-anhydropyrimidine test article to mitigate MTX-induced loss ofmucosal permeability. C57Bl/6 female mice (n=7) were treated (ip) with100 mg/kg MTX on days 2, 3 and 4 with and without 60 mg/kg TK-112690(ip) three hours before, and after, MTX injections. On day 7, mucosalbarrier injury was estimated by measuring plasma concentrations oforally administered iodixanol determined by HPLC using UV detection.Orally administered iodixanol is not absorbed absent an increase inmucosal permeability.

Data from the study are provided in FIG. 3. In this Figure, Group 1 isthe saline control treated animals, Group 2 is the methotrexate alonetreated animals and Group 3 is the methotrexate plus TK-112690 treatedanimals. Mice treated with 100 mg/kg MTX on Days 2, 3 and 4 experiencedmucosal barrier injury indicated by increased plasma concentration oforally administered iodixanol. Co-administration of 60 mg/kg TK-112690three hours before and three hours after MTX protected mice fromMTX-induced mucosal barrier injury indicated by reduced plasmaconcentration of orally administered iodixanol. The results werestatistically significant (p<0.05).

In summary, MTX administered ip to mice caused small intestinal mucosalbarrier injury indicated by increased plasma concentration of orallyadministered iodixanol, and co-administration of TK-112690 with MTXprotects against MTX-induced mucosal barrier injury indicated byreduction in plasma concentration of orally administered iodixanol.

IV. Mouse Study III (Infection Study)

The aim of this study is to examine the ability of a representative a2,2′-anhydropyrimidine test article to mitigate MTX-induced infectionmeasured as white blood cell counts in a mammal. Infection isrepresentative of MTX-induced toxicity, and one aspect of MTX-inducedmucositis.

Several parameters have been examined in an effort to develop a model toconfirm the protection from mucositis observed in the LPS/MTX assay. Onexamination of complete blood counts (CBCs), consistently elevatedlevels of white blood cell counts (WBCs) are observed when mice aretreated with MTX (FIG. 4). This increase is not observed in animals thatare also treated with TK-112690 (FIG. 4). These results can be bestunderstood by recalling that MTX damages the mucosal surface andgenerates a breach in the integrity of the intestinal lining, exposingthe underlying tissues to bacteria. LPS is a large molecule on the outermembrane of Gram negative bacteria. Tissues exposed to LPS expresspro-inflammatory cytokines such as TNF-α and IL-10. Increases in thesecytokines due to exposure of tissues to LPS generate an immune responsewhich, in turn, increases WBCs.

For the study whose data are presented in FIG. 4, C57BL/6 mice(n=10/dose group) were treated i.p. with 50 mg/kg MTX on Day 1, 2, 3, 4,6 and 8 along with 60 mg/kg TK-1126901.p. 3 hr±MTX followed by singledaily doses TK-112690 on days not treated with MTX. On Day 11, theanimals were bled and hematology performed on the resulting bloodsamples. Following the hematology measurements, the animals weresacrificed.

The data provided in FIG. 4 suggests that MTX treatment increasessystemic WBC (the WBC level in methotrexate treated animals isstatistically higher (p<0.02) than level in either saline orMTX+TK-112690 treated animals, which are not statistically differentfrom one another). In summary, TK-112690 protects from MTX-inducedmucositis, and that this effect can be measured by prevention ofincreases in WBC counts in MTX treated mice.

V. Cell Culture Study I (CCRF-CEM Human Leukemia Cells)

The aim of this study is to examine the ability of a representative a2,2′-anhydropyrimidine test article to not interfere with the desiredactivity of MTX in vitro.

The following are typical data derived from screening in the humancancer cell line CCRF-CEM, which show that TK112690, a representative2,2′-anhydropyrimidine test article, does not interfere withmethotrexate cytotoxicity in this human leukemia cell line. The tumorcell line CCR-CEM (human T-cell acute lymphoblastic leukemia) isobtained from American Type Culture Collection (CRL-1593.2) and culturedin accordance with the product information sheet with the followingexceptions: 55.3 cm² Petri dishes are used instead of 75 cm² cultureflasks, and 1% penicillin-streptomycin solution (HyClone SV30010) and 1%GlutaMAX™ (Gibco 35050) are added to the culture medium.

TK-112690, the representative 2,2′-anhydropyrimidine test article, isdissolved in 40% DMSO, sterile filtered then diluted with steriledistilled water to obtain initial working solutions of 10, 100 and 1000μM. In testing, a 100 fold dilution is made in culture media to givefinal assay concentrations of 0.1, 1.0 and 10.0 μM. MTX (SAFCBiosciences M8407) is dissolved in sterile distilled water and 5 N NaOHthen sterile filtered. The final pH of the stock solution is 7.8 andworking solutions are made with sterile distilled water for final assayconcentrations of 30, 3.0, 0.3, 0.03 and 0.003 μM. Leucovorin (SigmaF-7878) is dissolved in sterile distilled water, sterile filtered anddiluted with sterile distilled water for final assay concentrations of0.1, 1.0 and 10.0 μM.

Aliquots of 100 μL of cell suspension are plated in 96 well microtiterplates (Corning costar 3595) and placed in an atmosphere of 5% CO₂ at37° C. (Fisher Scientific Isotemp 3500 CO₂ Incubator). After 24 hours,100 μL of growth medium [RPMI-1640 w/L-glutamine (Cambrex 12-702Q)fortified with sodium pyruvate (HyClone SH30239.01), fetal bovine serum(SAFC Biosciences 12107C) and HEPES buffer (Gibco 15630)] and 2 μL oftest solution or vehicle are added respectively per well and the platesincubated for an additional 72 hour incubation. MTX is evaluated atconcentrations of 0.003, 0.03, 0.30 and 3.0 μM alone or in combinationwith either a 2,2′-anhydropyrimidine test article or Leucovorin atconcentrations of 0.1, 1.0, 10.0 μM. At the end of incubation, theefficacy of anti-cell proliferation is determined by optical absorbanceat λ=570 and 600 nm [Spectramax 250 (Molecular Devices)] in accordancewith the standard alamarBlue™ (Biosource) protocol.

FIG. 5 depicts a typical set of data demonstrating that the test articledoes not interfere with MTX cytotoxicity. Group 1 is the cell control(media treated). Group 2 corresponds to cells treated with 0.03 μM MTX.Group 3 are cells treated with 1.0 μM Leucovorin. Group 4 are cellstreated with 0.1 μM Leucovorin. Group 5 are cells treated with 10 μMTK-112690. Group 6 are cells treated with MTX+10 μM TK-112690. Group 7are cells treated with MTX+1.0 μM TK-112690. Group 8 MTX+0.1 μMTK-112690.

Group 2 (methotrexate alone) is statistically significantly differentfrom Group1, 3, 4, 5, 6 and 7 (p<0.000, 0.000, 0.000, 0.000, 0.000,0.000, respectively) but not different than the MTX+TK-112690 Groups(Groups 6, 7 and 8 (p<0.844, 0.918 and 1.000, respectively). TheLeucovorin+MTX groups (Groups 3 and 4) are statistically different thanGroup 2 (p<0.000 and 0.002, respectively) demonstrating protection bythe positive control.

This human cell culture study illustrate that 2,2′-anhydropyrimidineslike TK-112690 do not interfere with methotrexate cytotoxicity in ahuman lymphoma cell culture model.

VI. Mouse Study IV (Xenograft with CCRF-CEM Implants)

The aim of this study is to examine the ability of a representative a2,2′-anhydropyrimidine test article to not interfere with the desiredactivity of MTX in vivo.

A xenograft study was performed to analyze the effect of TK-112690.administration on the in vivo efficacy of MTX against a human cancer.Human CCRF-CEM (T-ALL) cells were implanted subcutaneously into SCIDmice. Tumor volumes were recorded on a regular basis, and once tumorshad become established, treatment was given. Tumor volumes from day 27of this experiment are shown in FIG. 6. Group 1 in this chart showsanimals that received only saline. Group 2 shows animals treated withMTX, and Group 3 contains data from animals that received both MTX and30 mg/kg TK-112690. All treatments were given ip, and TK-112690 was give3 hours prior to and 3 hours after MTX administration. The results shownin FIG. 6 demonstrate that saline treated groups are significantlydifferent from both treatment groups (p<0.01), however both treatmentgroups were not significantly different (p=1).

VII. Cell Culture Study II (AS283 Human Lymphoma Cells)

The aim of this study is to examine the ability of a representative a2,2′-anhydropyrimidine test article to not interfere with the desiredactivity of MTX in vitro.

The following are typical data derived from screening in the humancancer cell line AS283, which show that TK112690, a representative2,2′-anhydropyrimidine test article, does not interfere withmethotrexate cytotoxicity in this human lymphoma cell line.

AS283 cells were grown in RPMI-1640 supplemented with L-glutaminedipeptide, sodium pyruvate, HEPES, and 10% FBS. AS283 cells were grownto seed three 96-well plates with 10,000 cells/well in a total volume of50 μL. 100 μL medium in medium alone wells was seeded. Plates wereincubated overnight. The following day, 25 μL of the MTX and TK-112690stock solutions were added to the appropriate wells. TK-112690 was addedfirst, followed by MTX in all wells. 25 μL of vehicle was added toTK-112690 alone wells. 25 μL of vehicle and 25 μL medium were added tovehicle control wells, and 50 μL medium was added to cell control wells.10 μM doxorubicin was added as the positive control. TK-112690concentrations were 1, 10 and 100 μM. The MTX concentrations were 0.01,0.03, 0.1, 0.3, 1.0, 3.0, 10, 100 μM. Cell viability was measured usingCellTiter-Glo and DOX (10 μM) was used as a reference standard.

The plates were incubated at 37° C., 5% CO₂ for 72 hours then removedfrom the incubator and placed on the bench at room temperature for 30min. The plates were not stacked or shaken. 100 μL CellTiter-Glo reagentwas added and mixed for 2 min, followed by a further 10 min incubationat room temperature. Luminescence was recorded on TriLux.

IC₅₀ curve for MTX and MTX+TK-112690 at 100 and 10 μM and MTX andMTX+TK-112690 1.0 μM are provided in FIG. 7. There is no statisticaldifference between cell viability in MTX test wells and test wells withMTX+TK-112690 (1, 10, 100 μM). Therefore, the antiproliferative activityof MTX is not altered by the addition of TK-112690. This human cellculture study illustrate that 2,2′-anhydropyrimidines like TK-112690 donot interfere with methotrexate cytotoxicity in a human lymphoma cellculture model.

VIII. Mouse Study V (Xenograft with AS283 Implants)

The aim of this study was to determine whether TK-112690 affects MTXanti-tumor efficacy against subcutaneously (sc) implanted AS283 humanlymphoma xenografts in male C.B.-17 SCID mice. MTX administered alonewas used as the control.

Six-week-old male C.B.-17 SCID mice were acclimated in the laboratoriesfor seven days prior to experimentation. Thirty-to-forty mg fragments ofAS283 human lymphoma tumor were implanted sc in mice near the rightflank using a 12-gauge trocar needle and allowed to grow. Tumors wereallowed to reach 75-198 mg in weight (75-198 mm³ in size) before thestart of treatment. A sufficient number of mice were implanted so thattumors in a weight range as narrow as possible were selected for thetrial on the day of treatment initiation (day 8 after tumorimplantation). Those animals selected with tumors in the proper sizerange were assigned to the various treatment groups so that the mediantumor weights on the first day of treatment were as close to each otheras possible (162 mg for all groups). The experiment consisted of twotreatment groups and one vehicle-treated control group with ten animalsper group for a total of 30 mice on the first day of treatment.

A 15 mg/mL solution of TK-112690 was prepared daily by dissolving thecompound in 100% DMSO (by vortexing as needed) and then adding PBS for a3 mg/mL dosing solution. The final composition of the vehicle was 20%DMSO/80% PBS. The 25 mg/mL stock solution of MTX for injection wasdiluted each day of injection with saline to a 0.75 mg/mL dosingsolution. Both compounds were administered ip by exact body weight usingan injection volume of 0.1 mL for every 10 g of body weight.

TK-112690 was administered by intraperitoneal (ip) injection [twiceevery 2 days for 5 injections with six hour interval (q6h×2, q2d×5)] ata dosage of 30 mg/kg/injection. MTX was administered by intraperitoneal(ip) injection q2d×5 at a dosage of 5.0 mg/kg/injection three hoursafter the TK-112690 injection. The control group was treated with bothvehicles, which were administered on the corresponding compoundschedules.

The sc tumors were measured and the animals were weighed thrice weeklystarting the day of the first treatment. Tumor volume was determined bycaliper measurements (mm) and using the formula for an ellipsoid sphere:L×W²/2=mm³, where L and W refer to the larger and smaller perpendiculardimensions collected at each measurement. This formula is also used tocalculate tumor weight, assuming unit density (1 mm³=1 mg).

The study was terminated twenty one days after tumor implantation. Anyanimal found moribund or any animal whose tumor reached 4,000 mg,ulcerated or was sloughed off was euthanized prior to study termination.

Tumor volumes on Day 21 are provided in FIG. 8. In this Figure, Group 1is animals treated with the saline control, Group 2 is animals treatedwith MTX and Group 3 is animals treated with MTX+TK-112690. Tumors inthe vehicle-treated control group grew to the evaluation point in allten mice. The median tumor reached 4,387 mg in 21 days. The MTXtreatment delayed the growth of AS283 lymphoma xenografts with a mediantumor weight value 2.8% of the control on day 21 and a median tumorweight value of 24.7% (40.0 mg) smaller than the median tumor weightvalue at the start of treatment (162 mg). Administration of TK-112690combined with MTX delayed the growth with a median tumor weight value3.5% of the control on day 21 and a median tumor weight value 5.6% (9.0mg) smaller than the median tumor weight value at the start of treatment(162 mg). There was no statistical difference between the MTX (Group 2)and MTX+TK-112690 (Group 3) tumor volumes (p=1.0) but both groups werestatistically highly different (p<0.01) than the tumor volumes for thesaline treated animals (Group1).

IX. Study with Mouse and Human Intestinal Tissue Homogenates

The aim of this study was to evaluate TK-112690 in vivo as an inhibitorof uridine phosphorylase (UPase) enzyme activity. The range of TK-112690doses studied for ability to prevent metabolic breakdown of uridine,through the in vitro inhibition of mouse and human small intestinalUPase enzyme, was 0, 0.1, 0.5, 1, 5, 10, 50, 100, 500, 1000, 5000 and10000 μM). Detection of UPase activity was determined by HPLC analysisusing UV detection of uracil concentration (UPase catabolizes uridineinto uracil and ribose-1-phosphate).

The UPase enzyme material was prepared from homogenized mouse and humanbeing small intestinal tissue. TK-112690 was dissolved in water (50mg/ml) and analyzed for UPase inhibition in aqueous solution containing5 mM uridine, 0.01 M Tris, 0.01 M phosphate, 1 mM EDTA, and 1 mM DTT.Reactions were performed at 37° C. at pH of 7.3.

TK-11260 inhibition of mouse and human UPase was analyzed by reversephase HPLC using UV detection. HPLC analysis was performed at ambienttemperature with a Water 2695 Alliance system equipped with a C18ECONOSIL 5 U ALLtech column. 20 μl of UPase reaction samples wereauto-injected onto column. Mobile phase consisted of water eluting forfirst 2.5 ml and acetonitrile gradient to 100% in 12.5 ml (flow rate 0.5ml/min). The outlet fluent was monitored by UV absorption in the rangeof 240-320 nm. UPase enzymatic activity was based on the AUC of theuracil peaks.

Typical results are provided in FIG. 9. TK-112690 is seen to inhibitmouse small intestinal UPase enzyme, with a IC₅₀ value of 12.5 μM.TK-112690 inhibits human small intestinal UPase enzyme, with a an IC₅₀value of 20.0 μM.

X. Fly Study II (UPase Knockout Fly)

The aim of this study was to evaluate the lethal effects of a range(0.001, 0.01, 0.05, 0.1, 0.2, 0.4 mg) of doses of orally fed MTX inwild-type (Ore-R) and UPase mutant Drosophila melanogaster. Embryos ofUPase knockout (19519) Drosophila melanogaster were orally exposed to adose range of MTX (0.001, 0.01, 0.05, 0.1, 0.2, 0.4 mg) in food admix.Embryos of Wild-type (Oregon-R) were orally exposed to the same doserange of MTX in presence and absence of 0.04 mg TK-112690. Scoring wasbased on life or death 15 days after initiation of MTX exposure.

Typical results are provided in FIG. 10. UPase knockout D. melanogaster(19519) is seen to be resistant to lethal effects of a dose-range(0.001, 0.01, 0.05, 0.1, 0.2, 0.4 mg) of orally administered MTX.Wild-type D. melanogaster is sensitive to lethal effects of ≧0.1 mg MTX.However, wild-type D. melanogaster is resistant to the lethal effects ofa wide (0.001, 0.01, 0.05, 0.1, 0.2, 0.4 mg) range of orallyadministered doses of MTX if 0.04 mg TK-112690 is also present.

In summary, UPase knockout D. melanogaster are resistant to lethaleffects of orally fed MTX, whereas wild-type D. melanogater aresensitive to MTX but are resistant to orally fed MTX in the presence ofa UPase inhibitors like TK-112690

XI. Mouse Study VI (Plasma Uridine Following TK-112690 Treatment)

The aim of this study was to evaluate a range of TK-112690 dosesadministered to CD-1 mouse to evaluate the ability of TK-112690 toincrease plasma uridine concentration through UPase inhibition.

Plasma uridine concentration was determined by HPLC using UVdetectionafter animals were treated with TK-112690 as follows. TK-112690was dissolved in PBS to achieve a concentration of 500 mg/mL. CD-1female mice were injected ip with a range of TK-112690 doses (0, 15, 30,60 and 120 mg/kg) and plasma from the animals analyzed for TK-112690uridine concentrations expected to be elevated through UPase inhibitionby TK-112690. Plasma uridine concentrations were determined from plasmasamples collected 0.08, 0.50, 1, 2, 4 or 12 hours post TK-112690injection.

HPLC analysis was done at room temperature using a ThermoFinniganSpectra System equipped with degasser, pump, autosampler and UVdetector. Chromatograms will be constructed from a chart recorderequipped with a pen. Analytes were separated using a Phenomenex C₁₈Reverse-Phase column (250×4.6 mm). Table 2 describes gradient conditionsof two separate mobile phases employed during HPLC analysis: (1) 5%methanol in nano water with 0.1% formic acid (2) 5% Methanol inAcetonitrile with 0.1% Formic acid (Flow rate=0.5 mL per minute).

TABLE 2 Gradient Conditions HPLC Method for Plasma Uridine and TK-1126905% Methanol in nano 5% Methanol in Acetonitrile, Time water, 0.1% FormicAcid 0.1% Formic Acid  0:00 minutes 100% 0% 10:00 minutes  70% 30% 10:01minutes  0% 100% 20:00 minutes  0% 100% 20:01 minutes 100% 0% 40:00minutes 100% 0%10 μL samples were auto injected onto column. Uridine, TK-112690 and5-FU were identified by UV absorption at 262 nm. HPLC needle andinjector were washed with nano water before each sample run.

The retention times of uridine, TK-112690 and 5-FU are 9.3, 8.9 and 7.7minutes, respectively.

The micromolar concentration of plasma uridine was determined by linearequation (y=mx+b) generated from uridine and 5-FU calibration curve. They value is calculated by taking ratio of peak heights (mm) of uridineand 5-FU. All peak heights from HPLC chromatograms were measured inmillimeters using a ruler.

An identical approach was employed to quantitate TK-112690 in thesamples except the response for TK-112690 was attenuated by a responsefactor determined from the injection into the HPLC of identical amountsof TK-112690 and uridine,

Typical findings from the study are provided in FIG. 11. Plasmaconcentrations of TK-112690 increased with increasing doses of TK-112690administered ip. An increase in plasma uridine is noted almostimmediately following administration of TK-112690, At 0.5 hour postTK-112690 dose, a 100 μg/mL plasma concentration TK-112690 is associatedwith a plasma uridine concentration of approximately 2 μg/mL of uridine(baseline uridine concentration approximately 0.5 μg/mL).

XII. Synthesis of New UPase Inhibitors

A. Procedure for the Coupling of Nucleobases to Ribose Tetraacetate

The nucleobase 1A-D (2.0 equivalents) was dissolved in dry acetonitrile(2 mL per mmol). N,O-bis-trimethylsilylamide (4.0 equivalents) was addedand the mixture stirred at room temperature until clear (1-24 hours).The solution was cooled to 0° C. A solution of ribose tetraacetate (2)(1.0 equiv.) in dry CH₃CN (5 mL per mmol) was added slowly, followed bySnCl₄ (1.2 equiv.). The solution was stirred at room temperatureovernight. The reaction was quenched with the careful addition ofsaturated aqueous sodium bicarbonate. A solution of 1M aqueous HCl wasthen carefully added, and the mixture stirred for one hour. The solutionwas extracted three times with ethyl acetate. The combined organics werewashed with 1M HCl, water, saturated sodium bicarbonate and brine. Theorganic fraction was then dried over Na₂SO₄, filtered, and condensed invacuo to give a crude residue that was purified by flash columnchromatography (gradient, 99:1 to 90:10 chloroform:methanol) to givetriacetylated ribonucleoside 3A-D.

3A: ¹H NMR (500 MHz, CDCl₃) δ=9.56 (bs, 1H), 7.44 (t, J=1.5 Hz, 1H),6.16 (d, J=4.0 Hz, 1H), 5.36-5.32 (m, 2H), 4.32 (s, 2H), 4.24 (dd,J=2.0, 13.0 Hz, 1H), 4.19 (dd, J=1.5, 13.0 Hz, 1H), 3.40 (s, 3H), 2.17(s, 3H), 2.12 (s, 3H), 2.07 (s, 3H)

3B: ¹H NMR (500 MHz, CDCl₃) δ=11.35 (bs, 1H), 7.94 (s, 1H), 5.78 (d,J=5.5 Hz, 1H), 5.37 (d, J=6.0 Hz, 1H), 5.10-5.09 (t, J=5.0 Hz, 1H), 5.07(d, J=5.0 Hz, 1H), 4.09-4.00 (m, 3H), 3.95 (q, J=5.0 Hz, 1H), 3.83 (q,J=3.5 Hz, 1H), 3.62 (ddd, J=5.5, 8.5, 12.0 Hz, 1H), 3.53 (dt, J=4.5,12.0 Hz, 1H), 3.41 (dq, J=1.5, 7.0 Hz, 2H), 3.32 (s, 2H), 1.09 (t, J=7.0Hz, 3H)

3C: ¹H NMR (500 MHz, CDCl₃) δ=9.01 (bs, 1H), 7.50 (m, 1H), 7.38-7.30 (m,5H), 6.14-6.12 (m, 1H), 5.35 (d, J=4.0 Hz, 1H), 4.70 (s, 1H), 4.60 (s,2H), 4.37-4.29 (m, 5H), 2.14 (s, 3H), 2.10 (s, 3H), 1.99 (s, 3H)

3D: ¹H NMR (500 MHz, CDCl₃) δ=9.64 (bs, 1H), 7.37-7.25 (m, 5H), 6.43(bs, 1H), 6.17 (s, 2H), 6.11 (d, J=5.5 Hz, 1H), 5.80 (dd, J=2.5, 6.5 Hz,1H), 5.67 (dd, J=6.5, 8.0 Hz, 1H), 5.23-5.18 (m, 2H), 4.3-4.1 (m, 2H),2.09 (s, 3H), 2.08 (s, 3H), 2.05 (s, 3H)

B. Representative Procedure for Acetate Hydrolysis Reaction

Ribonucleoside tetraacetate 3A-D was dissolved in a 7N solution ofammonia in methanol. The solution was stirred overnight at roomtemperature. The solution was then reduced in vacuo. The resultantresidue was triturated with ether to give the free ribonucleoside as awhite solid that was isolated by filtration and dried under high vacuumbefore the next step.

C. Representative Procedure for Ring Closure Reactions

Method A: The ribonucleoside (1.0 equiv.) was dissolved in anhydrousdimethylacetamide (100 μL per mmol). Diphenylcarbonate (1.0 equiv.) andsodium bicarbonate (0.05 equiv.) were added and the mixture was stirredat 150° C. for one hour. Ether was added to precipitate the product as agum.

The solvent was decanted and the crude residue was purified by eitherflash column chromatography or preparative HPLC.

Method B: The ribonucleoside (1.0 equiv.) was dissolved in anhydrousdimethylformamide (100 μL per mmol). Diphenylcarbonate (1.0 equiv.) andsodium bicarbonate (0.05 equiv.) were added and the mixture was stirredat 100° C. for 8-12 hours. Ether was added to precipitate the product asa gum. The solvent was decanted and the crude residue was purified byeither flash column chromatography or preparative HPLC.

5A: ¹H NMR (500 MHz, DMSO_(d6)) δ=7.73 (s, 1H), 6.34 (d, J=5.7 Hz, 1H),5.86 (d, J=4.3 Hz, 1H), 5.19 (d, J=5.7 Hz, 1H), 4.95 (t, J=5.0 Hz, 1H),4.37 (d, J=4.3 Hz, 1H), 4.10-4.04 (m, 2H), 3.30 (s, 3H)

5B: ¹H NMR (500 MHz, DMSO_(d6)) δ=7.71 (s, 1H), 6.36 (d, J=5.7 Hz, 1H),5.88 (bs, 1H), 5.19 (d, J=5.7 Hz, 1H), 4.95 (t, J=5.2 Hz, 1H), 4.41 (bs,1H), 4.11 (dd, J=1.4, 4.0 Hz, 2H), 3.49 (q, J=7.0 Hz, 2H), 3.28-3.22 (m,1H), 3.19-3.13 (m, 1H), 1.14 (t, J=7.0 Hz, 3H)

5C: ¹H NMR (500 MHz, DMSO_(d6)) δ=7.79 (t, J=1.5 Hz, 1H), 7.38-7.34 (m,4H), 7.32-7.27 (m, 1H), 6.36 (d, J=5.5 Hz, 1H), 5.88 (bs, 1H), 5.74 (s,1H), 5.20 (d, J=5.5 Hz, 1H), 4.96 (t, J=5.0 Hz, 1H), 4.56 (s, 2H), 4.38(bs, 1H), 4.20-4.19 (m, 2H), 4.09-4.05 (m, 2H), 3.28-3.27 (m, 1H),3.19-3.15 (m, 3H)

5D: ¹H NMR (500 MHz, DMSO_(d6)) δ=7.31 (m, 4H), 7.22 (m, 1H), 6.64 (s,1H), 6.20 (d, J=5.7 Hz, 1H), 5.83 (d, J=3.9 Hz, 1H), 5.46 (t, J=6.4 Hz,1H), 5.10 (d, J=5.7 Hz, 1H), 4.93 (t, J=5.3 Hz, 1H), 4.33 (bs, 1H),4.17-4.05 (m, 3H), 3.99 (t, J=5.3 Hz, 1H), 3.18-3.14 (m, 2H), 3.05-3.00(m, 1H)

D. 2,2′-anhydro-5′-Fluoro-5-methyluridine

5-methyluridine-2′,3″-acetonide 6 (5.6 g, 18.8 mmol, 1.0 equiv.) wasdissolved in anhydrous dichloromethane (80 mL) and cooled to 0° C.Imidazole (2.6 g, 37.6 mmol, 2.0 equiv.) andtert-butylchlorodiphenylsilane (2.8 g, 18.8 mmol, 1.0 equiv.) were addedand the mixture was allowed to warm to room temperature and stirred forone hour. The dichloromethane was removed by rotary evaporation and theresidue was dissolved in 200 mL ethyl acetate, washed with waterfollowed by brine, and dried over Na₂SO₄. Following filtration andsolvent removal, the compound was purified by flash columnchromatography to give 7 (6.8 g, 88%). ¹H NMR (500 MHz, CDCl₃) δ=9.13(s, 1H), 7.31 (s, 1H), 5.92 (d, J=3.0 Hz, 1H), 4.76 (dd, J=3.0, 6.5 Hz,1H), 4.72 (dd, J=2.0, 6.5 Hz, 1H), 4.27 (q, J=3.0 Hz, 1H), 3.91 (dd,J=2.5, 11.5 Hz, 1H), 3.80 (dd, J=3.5, 11.5 Hz, 1H), 1.91 (s, 3H), 1.58(s, 3H), 1.35 (s, 3H), 0.90 (s, 9H), 0.09 (s, 3H), 0.09 (s, 3H); ¹³C NMR(125 MHz, CDCl₃) δ=163.98, 150.32, 136.35, 114.26, 110.80. 91.95, 86.11,84.73, 80.36, 63.27, 27.21, 25.83, 25.30, 18.31, 12.40, −5.44, −5.54

Compound 7, (4.8 g, 1.0 equiv.) was dissolved in a 4:1 mixture ofpyridine and CH₂Cl₂ (75 mL). Boc anhydride (5.2 g, 4.0 equiv.) wasadded, followed by DMAP (200 mg, cat.) and the solution was stirred atroom temperature overnight. The solvent was removed by rotaryevaporation and the residue was purified by flash column chromatographyto give 8 (4.8 g, 80%). ¹H NMR (500 MHz, CDCl₃) δ=7.31 (s, 1H), 5.82 (d,J=3.0 Hz, 1H), 4.74 (dd, J=3.0, 6.0 Hz, 1H), 4.71 (dd, J=2.5, 6.0 Hz,1H), 4.28 (q, J=3.0 Hz, 1H), 3.87 (dd, J=3.0, 11.5 Hz, 1H), 3.75 (dd,J=1.5, 11.5 Hz, 1H), 1.88 (s, 3H), 1.56 (s, 9H), 1.53 (s, 3H), 1.32 (s,3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H) ¹³C NMR (125 MHz, CDCl₃)δ=161.45, 148.41, 147.80, 136.68, 114.04, 110.14, 92.82, 86.60, 84.96,80.46, 63.28, 27.32, 27.15, 25.78, 25.24, 18.23, 12.48, −5.51, −5.58

Compound 8, (4.8 g, 1.0 equiv.) was dissolved in anhydrous THF (333 mL).TBAF (14 mL, 1M in THF, 1.5 equiv) was added in one portion and thesolution was stirred for 2 hours at room temperature. Solvent wasremoved by rotary evaporation and the resultant residue was purified byflash column chromatography to give 9 (2.7 g, 72%). ¹H NMR (500 MHz,CDCl₃) δ=7.18 (s, 1H), 5.54 (d, J=3.0 Hz, 1H), 5.08 (dd, J=3.0, 6.0 Hz,1H), 4.97 (dd, J=4.0, 7.0 Hz, 1H), 4.27 (q, J=3.0 Hz, 1H), 3.20 (dd,J=2.5, 12.5 Hz, 1H), 3.79 (dd, J=3.0, 12.5 Hz, 1H), 1.93 (s, 3H), 1.60(s, 9H), 1.57 (s, 3H), 1.36 (s, 3H)

Compound 9 (2.2 g, 1.0 equiv.) was dissolved in anhydrous THF under anatmosphere of nitrogen. Tosyl fluoride (1.92 g, 2.0 equiv.) was added,followed by 16.5 mL of a 1M solution of TBAF in THF (3.0 equiv.) Themixture was heated to 60° C. and stirred at this temperature for 12hours. Upon cooling, the solvent was removed and the residue purified byflash column chromatography to give compound 10, (1.76 g, 80%). ¹H NMR(500 MHz, CDCl₃) δ=7.13 (s, 1H), 5.83 (s, 1H), 4.93-4.91 (m, 1H), 4.87(dd, J=4.0, 6.5 Hz), 4.75-4.57 (m, 2H), 4.41-4.35 (m, 1H), 1.93 (s, 3H),1.60 (s, 9H), 1.58 (s, 3H), 1.36 (s, 3H)

Compound 10 (1.6 g, 1.0 equiv.) was dissolved in 16 mL of 50% aqueousTFA and stirred for two hours. The solvent was removed by rotaryevaporation and azeotroped three times with toluene, followed by twotimes with CH₂Cl₂ to give 1.09 g (quant.) of the fully deprotectedcompound 11 as a white foam. ¹H NMR (500 MHz, DMSO_(d6)) δ=11.36 (s,1H), 7.39 (s, 1H), 5.78 (d, J=5.0 Hz, 1H), 4.70-4.63 (m, 1H), 4.60-4.53(m, 1H), 4.04 (t, J=5.0 Hz, 1H), 3.99-3.93 (m, 2H), 1.78 (s, 3H)

Cyclization was performed via Method B above to give compound 12 as anoff-white solid (130 mg, purified by recrystallization fromethanol/ether). ¹H NMR (500 MHz, DMSO_(d6)) δ=7.70 (d, J=1.0 Hz, 1H),6.33 (d, J=5.5 Hz, 1H), 6.11 (bs, 1H), 5.21 (d, J=5.5 Hz, 1H), 4.45-4.25(m, 4H), 1.78 (s, 3H); ¹³C NMR (125 MHz, DMSO-d) δ=171.53, 159.34,132.07, 116.68, 94.19, 90.11, 88.10, 86.32, 86.19, 83.18, 81.84, 74.51,74.47, 13.27

E. 2,2′-anhydro-5′-Azido-5-methyluridine

To a solution of Compound 13 (2.52 g, 1.0 equiv.) in 16 mL of DMF wasadded sodium azide (1.74 g, 4.0 equiv.). The solution was allowed tostir at room temperature overnight and solvent was removed by rotaryevaporation. The crude product was purified by silica gel columnchromatography to give 14 (2.16 g, quantitative yield). ¹H NMR (500 MHz,CDCl₃) δ=10.11, (bs, 1H), 7.13 (d, J=1.5 Hz, 1H), 5.65 (d, J=1.5 Hz,1H), 5.05 (dd, J=2.0, 6.5 Hz, 1H), 4.84 (dd, J=4.5, 6.5 Hz, 1H), 4.24(dd, J=4.5 Hz, 10.5 Hz, 1H), 3.66-3.60 (m, 2H), 1.92 (d, J=1.5 Hz, 3H),1.56 (s, 3H), 1.35 (s, 3H)

Compound 14 (0.9 g, 1.0 equiv.) was deprotected in the same fashion ascompound 10. After azeotropic removal of solvent, the crude oil wastriturated with diethyl ether and the resulting solid was filtered anddried to yield 15 (0.42 g, 54%). ¹H NMR (500 MHz, DMSO_(d6)) δ=11.36(bs, 1H), 7.51 (s, 1H), 5.78 (d, J=6.0 Hz, 1H), 5.40 (bs, 1H), 5.25 (bs,1H), 4.15 (t, J=5.5 Hz, 1H), 3.94-3.88 (m, 2H), 3.59 (d, J=5.0 Hz, 2H),1.79-1.80 (m, 3H).

Cyclization of 15 (0.4 g, 1.4 mmol, 1.0 equiv.) was performed via MethodB and purified by silica gel column chromatography to give 16 (83 mg,22%). ¹H NMR (500 MHz, DMSO_(d6)) δ=7.80 (d, J=1.0 Hz, 1H), 6.33 (d,J=6.0 Hz, 1H), 6.05 (d, J=4.5 Hz, 1H), 5.22 (dd, J=1.0, 6.0 Hz, 1H),4.32-4.29 (m, 1H), 4.2 (ddd, J=2.5, 4.0, 7.5 Hz, 1H), 3.41 (dd, J=4.0,13.5 Hz, 1H), 3.18 (dd, J=7.5, 13.5 Hz, 1H), 1.79 (d, J=1.0 Hz, 3H).

XIII. Assay Results from Synthesized Compounds

Some compounds synthesized according to the approaches described inExperiment XII were evaluated using the test methods from Experiment I(Fly Study I, Protection from Lethality) and Experiment IX (Mouse Studywith Mouse and Human Intestinal Tissue Homogenates). The results of theevaluations are provided in Table 3.

TABLE 3 Comparison of Protection from Fly Lethality and UPase Inhibitionfor Synthesized Compounds Flies Alive UPase Desig- (Num- IC₅₀ Structurenation ber) (μM)

TK- 000006  0 <100

TK- 000007  3 <100

TK- 000008  0 <100

TK- 000009  5 <100

TK- 000010  0  >100.

TK- 000011 0 >100

TK- 000015 0 >100

TK- 000016  0 <100

TK- 112690  8 <100 — MTX  0 — Alone — Control 123   0Several compounds (TK-000006, TK-000007 TK-000008, TK-000009 andTK-100616) were active inhibitors of murine UPase (UPase IC₅₀<100 μM).One compound, TK000009, was also active in the Fly model for protectionagainst MTX-induced lethality. To date all compounds active in the Flymodel are also active UPase inhibitors. However, not all active UPaseinhibitors are also active protectants in the Fly model.

It is evident from the above results that the subject invention providesfor methods of reducing the toxicity of MTX active agents whileretaining their desired activity. As such, the subject invention findsuse in a variety of different applications and represents a significantcontribution to the art.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, it is readily apparent to those of ordinary skill in theart in light of the teachings of this invention that certain changes andmodifications may be made thereto without departing from the spirit orscope of the appended claims.

Accordingly, the preceding merely illustrates the principles of theinvention. It will be appreciated that those skilled in the art will beable to devise various arrangements which, although not explicitlydescribed or shown herein, embody the principles of the invention andare included within its spirit and scope. Furthermore, all examples andconditional language recited herein are principally intended to aid thereader in understanding the principles of the invention and the conceptscontributed by the inventors to furthering the art, and are to beconstrued as being without limitation to such specifically recitedexamples and conditions. Moreover, all statements herein recitingprinciples, aspects, and embodiments of the invention as well asspecific examples thereof, are intended to encompass both structural andfunctional equivalents thereof. Additionally, it is intended that suchequivalents include both currently known equivalents and equivalentsdeveloped in the future, i.e., any elements developed that perform thesame function, regardless of structure. The scope of the presentinvention, therefore, is not intended to be limited to the exemplaryembodiments shown and described herein. Rather, the scope and spirit ofpresent invention is embodied by the appended claims.

What is claimed is:
 1. A kit for use in treating a host suffering from acellular proliferative disease condition, said kit comprising: (a) anMTX active agent; and (b) an MTX toxicity-reducing adjuvant, whereinsaid MTX toxicity-reducing adjuvant is a 2,2′-anhydropyrimidine orderivative thereof.
 2. The kit according to claim 1, wherein said2,2′-anhydropyrimidine or derivative thereof is a compound of formula(I):

or the pharmaceutically acceptable salts, solvates, hydrates, andprodrug forms thereof, and stereoisomers thereof; wherein: each R¹, R²,R³, and R⁴ is independently selected from the group consisting ofhydrogen, substituted or unsubstituted heteroatom, substituted orunsubstituted alkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, substitutedor unsubstituted aralkyl, carbohydrate, nucleic acid, amino acid,peptide, dye, fluorophore and polypeptide.
 3. The kit according to claim2, wherein each R¹, R², R³, and R⁴ is independently selected fromselected from the group consisting of hydrogen, hydroxyl, sulfyhydryl,amino, hydroxymethyl, methoxy, halogen, pseudohalogen, and a substitutedor unsubstituted lower hydrocarbon containing 1 to 20 carbons.
 4. Thekit according to claim 3, wherein said lower hydrocarbon is selectedfrom the group consisting of alkyl, alkenyl, alkanoyl, aryl, aroyl,aralkyl and alkylamino, and esters thereof.
 5. The kit according toclaim 2, wherein R¹ is hydrogen, flourine, methyl, ethyl, propyl,benzyl, or 2-bromovinyl; R² is hydrogen, hydroxyl flourine, methyl,ethyl, propyl, benzyl, benzoyl, benzoyloxy, or 2-bromovinyl; and each R³and R⁴ is independently selected from the group consisting of hydroxyland benzoyloxy.
 6. The kit according to claim 2, wherein R¹ is hydrogenor methyl; R² is hydrogen; and each R³ and R⁴ is independently selectedfrom the group consisting of hydroxyl and benzoyloxy.
 7. The kitaccording to claim 2, wherein R¹ is hydrogen or methyl; R² is hydrogen,R³ is hydroxyl or benzoyloxy; and R⁴ is hydroxyl.
 8. The kit accordingto claim 1, wherein said 2,2′-anhydropyrimidine or derivative thereof isselected from the group consisting of: 2,2′-anhydro-5-methyluridine;3′-O-benzoyl-2,2′-anhydrouridine;3′-O-benzoyl-2,2′-anhydro-5-methyluridine;5′-O-benzoyl-2,2′-anhydrouridine; and5′-O-benzoyl-2,2′-anhydro-5-methyluridine.
 9. The kit according to claim1, wherein said 2,2′-anhydropyrimidine or derivative thereof is2,2′-anhydro-5-methyluridine.
 10. The kit according to claim 1, whereinsaid 2,2′-anhydropyrimidine or derivative thereof is3′-O-benzoyl-2,2′-anhydro-5-methyluridine.
 11. The kit according toclaim 1, wherein said 2,2′-anhydropyrimidine or derivative thereof is5′-O-benzoyl-2,2′-anhydro-5-methyluridine.
 12. The kit according toclaim 1, wherein said 2,2′-anhydropyrimidine or derivative thereofcomprises a stereoisomer.
 13. The kit according to claim 12, whereinsaid stereoisomer is selected from the group consisting of2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyluracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-uracil;3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyluracil;5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-uracil; and5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyluracil. 14.The kit according to claim 1, wherein said MTX active agent and MTXtoxicity-reducing adjuvant are present as separate compositions.
 15. Thekit according to claim 1, wherein said MTX active agent and MTXtoxicity-reducing adjuvant are present in the same composition.
 16. Akit for use in treating a host suffering from a cellular proliferativedisease condition, said kit comprising: (a) instructions for using a MTXtoxicity-reducing adjuvant, and (b) a pharmaceutical compositionincluding one or more of a MTX active agent, a MTX toxicity-reducingadjuvant, or a combination thereof, wherein said MTX toxicity-reducingadjuvant is a 2,2′-anhydropyrimidine or derivative thereof.